# Medical Question & Answer

**Sample ID**: 9d8e33f8-0548-43c8-9edd-d088511509ed
**Dataset Index**: 3702

---

## Question

Tricagrelor shortness of breath prevalence

---

## Answer

> Let's see… What do we have here? The user is asking about the prevalence of ticagrelor-associated shortness of breath (dyspnea). Let's break this down step-by-step. First, I need to think about the most authoritative sources, especially FDA labeling and pivotal trials. Then, I should verify the ranges reported across PLATO, PEGASUS, THEMIS, and ONSET/OFFSET. Next, I will check real-world and meta-analytic estimates and consider discontinuation rates. After that, I need to examine subgroup variations, including COPD and dose effects. Finally, I will synthesize a practical, clinically framed answer with counseling points and caveats about mechanisms and severity.

> Let me first confirm the highest-credibility anchor: the FDA labeling consistently reports that in clinical trials, about 14% (PLATO and PEGASUS) to 21% (THEMIS) of ticagrelor-treated patients developed dyspnea, and it emphasizes that dyspnea is usually mild to moderate and often resolves with continued therapy, which aligns with the core trial experience and is the most reliable single source for a population-level estimate [^114vo3uY] [^111FAcH4].

> Wait, let me verify the pivotal trial specifics so I don't overgeneralize. In PLATO, dyspnea occurred in 14.5% on ticagrelor vs 8.7% on clopidogrel, with severe dyspnea in 0.4% vs 0.3%, respectively, supporting both the absolute and relative excess with ticagrelor and the low severity burden in most cases [^114FLd1Y]. In PEGASUS-TIMI 54, discontinuation for dyspnea occurred in 6.5% with ticagrelor 90 mg and 4.6% with ticagrelor 60 mg vs 0.8% with placebo, reinforcing that dyspnea is a leading tolerability issue even when not life-threatening [^1134uPtU]. In THEMIS (stable CAD with diabetes), the FDA notes dyspnea around 21%, which is higher than in ACS cohorts, suggesting population context matters [^114vo3uY].

> Hold on, I should review mechanistic and physiologic substudies to ensure this isn't pulmonary pathology. The PLATO pulmonary function substudy showed no adverse changes in spirometry, lung volumes, or diffusion capacity with ticagrelor compared with clopidogrel, and ONSET/OFFSET similarly found no cardiac or pulmonary function changes despite a higher dyspnea incidence, which supports that ticagrelor-related dyspnea is typically subjective and benign from a cardiopulmonary standpoint [^115K7U4T] [^1138Gnvt].

> Next, I should review real-world and meta-analytic data to see if practice patterns differ from trials. A meta-analysis across four randomized trials quantified premature ticagrelor discontinuation at 25%, with dyspnea-related discontinuation about 6.4-fold higher than comparators, underscoring real-world adherence challenges even when symptoms are mild to moderate [^113xeL5W]. Observational cohorts also report higher dyspnea rates than trials; for example, a large ACS-PCI cohort found dyspnea in 27.3% with ticagrelor vs 22.6% with clopidogrel, and a registry showed dyspnea drove 29% of adverse-effect–related cessations, consistent with early, symptom-driven discontinuation patterns [^116W1cCE] [^1169tAzL].

> I need to check subgroup nuances, especially COPD, because absolute rates may be higher even if relative risk is similar. In PLATO COPD analyses, ticagrelor-associated dyspnea occurred in 26.1% vs 16.3% with clopidogrel, with no significant interaction by COPD status, indicating a higher absolute risk but similar relative excess; importantly, ticagrelor still reduced ischemic events without excess major bleeding in COPD, supporting continued use with counseling [^1164JyEC] [^116NwAmN]. Let me also consider dose: in PEGASUS, the 60 mg BID dose had lower dyspnea-related discontinuation than 90 mg BID, suggesting dose attenuation can mitigate symptoms when clinically appropriate [^1168T2Ae].

> But wait, what about mechanism and whether caffeine helps? The adenosine hypothesis is plausible given ENT1 inhibition, and ticagrelor augments adenosine-induced dyspnea in healthy volunteers while theophylline attenuates it; however, large observational analyses in PEGASUS did not show caffeine reducing overall dyspnea incidence, though there was a signal for less discontinuation, so I should be cautious not to overstate caffeine as a remedy despite biologic plausibility [^112VFAbF] [^112fJy5i] [^113uQECS].

> I should double-check timing and severity patterns to guide counseling. Discontinuation for dyspnea tends to occur early, often within 8–11 days of initiation, and most cases are mild to moderate; importantly, symptoms frequently abate with continued therapy, and pulmonary function remains unaffected, which should be emphasized to preempt premature discontinuation [^1113fyke] [^114vo3uY].

> Let me synthesize a clinically useful prevalence range and caveats. Across randomized trials, ticagrelor-associated dyspnea occurs in roughly 14–21% depending on the population, with an absolute excess of about 5–6% vs clopidogrel in ACS cohorts, and higher in some real-world and stable CAD populations; severe dyspnea is uncommon (around 0.4% in PLATO), and discontinuation for dyspnea ranges from about 1% in PLATO to 4–7% in longer-term secondary prevention trials, with real-world registries showing dyspnea-driven discontinuation near 29% of adverse-effect cessations, reflecting both symptom burden and patient expectations [^114vo3uY] [^114FLd1Y] [^1168T2Ae] [^1169tAzL].

> Finally, I need to ensure the counseling message is precise. Patients should be warned that ticagrelor can cause mild to moderate dyspnea, often early and frequently self-limited; new or worsening dyspnea warrants clinical review but, if ticagrelor-related, usually does not indicate lung injury and may improve with continued therapy; if truly intolerable, switching to an alternative P2Y12 inhibitor is reasonable, and dose reduction to 60 mg BID can be considered in selected cases to improve tolerability without sacrificing ischemic benefit [^111FAcH4] [^1168T2Ae].

---

Ticagrelor-associated dyspnea occurs in **14–21% of patients** in clinical trials [^114vo3uY], with a median onset within 1 week and most cases mild to moderate [^1138Gnvt]. Severe dyspnea occurs in about 0.4% and leads to discontinuation in 0.9–6.9% depending on the trial [^114FLd1Y] [^114vo3uY]. Real-world cohorts report a similar or slightly higher incidence (~22–27%) [^116W1cCE] and a higher discontinuation rate (~6–9%) [^1136sSbi]. Dyspnea is typically transient, not linked to pulmonary dysfunction [^115K7U4T], and may relate to adenosine accumulation [^115jaG6u]; management includes reassurance, dose reduction, or switching to clopidogrel or prasugrel if intolerable [^114vo3uY].

---

## Incidence of ticagrelor-associated dyspnea

### Clinical trial data

- **PLATO trial**: Dyspnea occurred in 14.5% of ticagrelor-treated patients vs 8.7% with clopidogrel; severe dyspnea in 0.4% vs 0.3% [^114FLd1Y].
- **PEGASUS-TIMI 54**: Dyspnea led to discontinuation in 4.3% (90 mg) and 2.8% (60 mg) vs 0.8% with placebo [^notfound].
- **THEMIS**: Dyspnea occurred in 20.9% vs 9.4% with placebo; discontinuation due to dyspnea in 6.9% vs 0.8% [^notfound].
- **ONSET/OFFSET**: Dyspnea in 38.6% with ticagrelor vs 9.3% with clopidogrel or placebo; most cases were mild and transient [^1138Gnvt].

---

### Real-world data

Real-world cohorts show a **similar or slightly higher incidence (~22–27%)** than in trials, with higher discontinuation rates (~6–9%) [^116W1cCE].

---

## Time course and severity

- **Onset**: Median onset is within 1 week; most cases occur early after initiation [^1138Gnvt].
- **Severity**: Predominantly mild to moderate; severe dyspnea in ~0.4% [^114FLd1Y].
- **Resolution**: Often resolves with continued therapy; median time to resolution is ~7 days [^114vo3uY].

---

## Clinical characteristics and risk factors

Clinical features are typically **transient, self-limited, and not associated with objective pulmonary dysfunction** [^115K7U4T]. Risk factors include **COPD, older age, obesity, prior PCI/CABG, and concomitant ARB use** [^1164JyEC] [^1136sSbi] [^116iZPTq].

---

## Mechanisms underlying ticagrelor-associated dyspnea

Mechanistic hypotheses include **adenosine accumulation** from ENT-1 inhibition, which augments dyspnea via C-fiber stimulation [^112VFAbF] [^114UhhjM], and a **direct CNS effect** whereby P2Y12 inhibition may modulate dyspnea perception centrally [^116bejsi].

---

## Clinical management strategies

- **Reassurance**: Educate patients that dyspnea is common, usually mild, and often transient [^114vo3uY].
- **Dose adjustment**: Consider reducing to 60 mg BID or switching to clopidogrel/prasugrel if intolerable [^114vo3uY].
- **Monitoring**: No routine pulmonary function testing unless clinically indicated [^1162aGGE].
- **Supportive care**: Use oxygen, beta-agonists, or anxiolytics as needed.

---

## Impact on clinical outcomes

Ischemic outcomes are **not adversely affected**; ticagrelor maintains efficacy despite dyspnea [^114FLd1Y]. Bleeding risk is **not increased** by dyspnea itself, though ticagrelor increases bleeding overall [^114ScKsd]. Quality of life may be transiently impacted, but **most patients continue therapy without long-term sequelae** [^1162aGGE].

---

Ticagrelor-associated dyspnea is **common but usually mild and transient**, with a median onset within 1 week. Management centers on **reassurance, dose adjustment, or switching therapy** if needed, and it does not negate ticagrelor's ischemic benefits.

---

## References

### Ticagrelor PO side effects [^116b1hCE]. FDA (2025). Medium credibility.

Very Common
- dyspnea

Common
- AF
- bleeding
- bradycardia
- hypertension
- hypotension
- back pain
- chest pain
- cough
- diarrhea
- dizziness
- fatigue
- headache
- nausea
- syncope

Uncommon
- ⚠ gynecomastia
- intracranial hemorrhage
- intracranial hemorrhage
- ↑ serum uric acid

Unknown Frequency
- atrioventricular block
- ⚠ angioedema
- apnea
- cheyne-Stokes breathing
- skin rash
- thrombotic thrombocytopenic purpura

---

### Ticagrelor [^114AXpCF]. FDA (2025). Medium credibility.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Advise patients daily doses of aspirin should not exceed 100 mg and to avoid taking any other medications that contain aspirin.

Advise patients that they:

Will bleed and bruise more easily
Will take longer than usual to stop bleeding
Should report any unanticipated, prolonged or excessive bleeding, or blood in their stool or urine.

Advise patients to contact their doctor if they experience unexpected shortness of breath, especially if severe.

Advise patients to inform physicians and dentists that they are taking ticagrelor before any surgery or dental procedure.

Advise women that breastfeeding is not recommended during treatment with ticagrelor [see Use in Specific Populations (8.2)].

Manufactured by:

Amneal Pharmaceuticals Pvt. Ltd. Oral Solid Dosage Unit

Ahmedabad 382213, INDIA

Distributed by: Amneal Pharmaceuticals LLC

Bridgewater, NJ 08807

Rev. 07–2025–06

---

### Ticagrelor (Brilinta) [^112wDFJL]. FDA (2024). Medium credibility.

Very common adverse reactions (over 10%) associated with the use of ticagrelor PO (also known as Brilinta) include: dyspnea.

---

### Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes [^114FLd1Y]. European Heart Journal (2011). Low credibility.

AIMS To describe the incidence of dyspnoea and its associations with demographic characteristics and clinical outcomes in patients with acute coronary syndromes (ACS) treated with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) study. METHODS AND RESULTS In the PLATO study, 18 624 patients were randomized to receive either clopidogrel [300–600 mg loading dose (LD), 75 mg daily] or ticagrelor (180 mg LD, 90 mg b.i.d.). The occurrence of reported dyspnoea adverse events (AEs) was analysed in the 18 421 patients who received at least one dose of study medication in relation to demographic characteristics, clinical outcomes and other associations of patients with and without dyspnoea. A total of 1339 ticagrelor-treated patients (14.5%) and 798 clopidogrel-treated patients (8.7%) had a dyspnoea AE following randomization, with respectively 39 (0.4%) and 24 (0.3%) classified as severe in intensity. Excluding dyspnoea AEs occurring after the secondary endpoint of myocardial infarction (MI), the yearly rates of the efficacy endpoints in dyspnoea AE patients in the ticagrelor and clopidogrel groups were: for the primary composite of CV death, MI, and stroke, 8.8 and 10.4% (unadjusted P = 0.25; adjusted P = 0.54); for CV death, 3.1 and 4.8% (unadjusted P = 0.024; adjusted P = 0.18); and for total death 3.7 and 6.2% (unadjusted P = 0.004; adjusted P = 0.06), respectively. CONCLUSIONS Ticagrelor-related dyspnoea is usually mild or moderate in intensity and does not appear to be associated with differences concerning any efficacy or safety outcomes with ticagrelor compared with clopidogrel therapy in ACS patients.

---

### Ticagrelor (Brilinta) [^117P777s]. FDA (2025). Medium credibility.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Advise patients daily doses of aspirin should not exceed 100 mg and to avoid taking any other medications that contain aspirin.

Advise patients that they:

Will bleed and bruise more easily
Will take longer than usual to stop bleeding
Should report any unanticipated, prolonged or excessive bleeding, or blood in their stool or urine.

Advise patients to contact their doctor if they experience unexpected shortness of breath, especially if severe.

Advise patients to inform physicians and dentists that they are taking BRILINTA before any surgery or dental procedure.

Advise women that breastfeeding is not recommended during treatment with BRILINTA [see Use in Specific Populations (8.2)].

BRILINTA®is a trademark of the AstraZeneca group of companies.

Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850

Distributed By:

Cardinal Health

Dublin, OH 43017

L50533760825

ER7198S Rev. B

© AstraZeneca 2024

---

### Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET / OFFSET study [^1138Gnvt]. Journal of the American College of Cardiology (2010). Low credibility.

Objectives

We prospectively assessed cardiac and pulmonary function in patients with stable coronary artery disease (CAD) treated with ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET (A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease) study.

Background

Ticagrelor reduces cardiovascular events more effectively than clopidogrel in patients with acute coronary syndromes. Dyspnea develops in some patients treated with ticagrelor, and it is not known whether this is associated with changes in cardiac or pulmonary function.

Methods

In all, 123 stable aspirin-treated CAD patients randomly received either ticagrelor (180 mg load, then 90 mg twice daily; n = 57), clopidogrel (600 mg load, then 75 mg daily; n = 54), or placebo (n = 12) for 6 weeks in a double-blind, double-dummy design. Electrocardiography, echocardiography, serum N-terminal pro-brain natriuretic peptide, and pulmonary function tests were performed before (baseline) and 6 weeks after drug administration and/or after development of dyspnea.

Results

After drug administration, dyspnea was reported by 38.6%, 9.3%, and 8.3% of patients in the ticagrelor, clopidogrel, and placebo groups, respectively (p < 0.001). Most instances were mild and/or lasted < 24 h, although 3 patients discontinued ticagrelor because of dyspnea. Eight of 22 and 17 of 22 ticagrelor-treated patients experiencing dyspnea did so within 24 h and 1 week, respectively, after drug administration. In all treatment groups, and in ticagrelor-treated patients with dyspnea, there were no significant changes between baseline and 6 weeks in any of the cardiac or pulmonary function parameters.

Conclusions

Dyspnea is commonly associated with ticagrelor therapy, but was not associated in this study with any adverse change in cardiac or pulmonary function. (A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease [ONSET/OFFSET]; NCT00528411).

---

### New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^115jaG6u]. Chest (2012). Medium credibility.

Ticagrelor adverse effects — reported side effects include dyspnea (usually mild and dose related), asymptomatic bradycardia with ventricular pauses, and a modest increase in uric acid; mechanisms are unclear, with a proposed role for adenosine reuptake inhibition leading to increased adenosine and potential effects independent of P2Y12 blockade.

---

### Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial [^1164JyEC]. Journal of the American Heart Association (2015). Low credibility.

Although there was no relative increase in ticagrelor‐related dyspnea in the COPD cohort, there was a higher absolute risk of dyspnea in these patients. Even though more than 1 quarter of the ticagrelor‐treated COPD patients experienced dyspnea, only 2.5% of these patients discontinued ticagrelor because of dyspnea, compared to 0.9% among ticagrelor‐treated patients without COPD. Furthermore, the number of SAEss related to dyspnea was few and none were fatal. Most important, the overall ischemic event rate was much lower in the ticagrelor‐treated COPD subset, despite the high incidence of dyspnea, in accord with previous studies of ticagrelor‐related dyspnea showing that it is often transient and usually mild to moderate in severity without any adverse effect on either lung or heart function. 14, 15, 25

Limitations

This study was a post‐hoc analysis not prespecified in the original trial design. The COPD cohort of 1085 patients was not powered to show a difference in the primary outcome between the randomized groups. The randomization in PLATO was not stratified for COPD status; therefore, some imbalance between the groups may exist among the subset of patients with COPD. Still, the COPD groups stratified by treatment were well balanced regarding baseline characteristics. Furthermore, because COPD status was assessed by the investigators and not based on pulmonary function tests, the COPD cohort may represent a more clinically evident and severe COPD phenotype. However, the assessments performed by the PLATO investigators probably reflect the routine clinical setting.

---

### Dyspnea-related ticagrelor discontinuation after percutaneous Coronary intervention [^1136sSbi]. JACC: Cardiovascular Interventions (2023). Medium credibility.

Background

Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases.

Objectives

The authors sought to evaluate the incidence, predictors, and outcomes of dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention (PCI).

Methods

In the TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) trial, after 3 months of ticagrelor plus aspirin, patients were maintained on ticagrelor and randomized to aspirin or placebo for 1 year. The occurrence of dyspnea associated with ticagrelor discontinuation was evaluated among all patients enrolled in the trial. A landmark analysis was performed at 3 months after PCI, that is, the time of randomization. Predictors of dyspnea-related ticagrelor discontinuation were obtained from multivariable Cox regression with stepwise selection of candidate variables.

Results

The incidence of dyspnea-related ticagrelor discontinuation was 6.4% and 9.1% at 3 and 15 months after PCI, respectively. Independent predictors included Asian race (lower risk), smoking, prior PCI, hypercholesterolemia, prior coronary artery bypass, peripheral artery disease, obesity, and older age. Among 179 patients who discontinued ticagrelor because of dyspnea after randomization, ticagrelor monotherapy was not associated with a higher risk of subsequent ischemic events (composite of all-cause death, myocardial infarction, or stroke) compared with ticagrelor plus aspirin (5.0% vs 7.1%; P = 0.566).

Conclusions

In the TWILIGHT trial, dyspnea-related ticagrelor discontinuation occurred in almost 1 in 10 patients and tended to occur earlier rather than late after PCI. Several demographic and clinical conditions predicted its occurrence, and their assessment may help identify subjects at risk for therapy nonadherence.

---

### Ticagrelor (Brilinta) [^115pmiNp]. FDA (2024). Medium credibility.

Warnings and precautions regarding the use of ticagrelor PO (also known as Brilinta):

- **Cardiac arrhythmias, bradycardia**: use caution in patients with a history of sick sinus syndrome, second or third degree AV block, or syncope.
- **Dyspnea**: maintain a high level of suspicion, as mild to moderate intensity dyspnea has been observed in patients treated with ticagrelor.
- **Exacerbation of central sleep apnea, Cheyne-Stokes respirations**: use extreme caution in patients with pre-existing central sleep apnea.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^115jWGuz]. Journal of the American Heart Association (2020). Medium credibility.

Results

Descriptive Statistics: Baseline Caffeine Intake

A total of 9694 participants were included in this analysis, of whom 9568 form the safety database. Median caffeinated beverage intake was 10 cups per week (interquartile range: 4–21). A total of 8406 patients reported drinking at least 1 cup of caffeinated beverage per week, whereas 1288 patients drank no caffeine. Caffeine intake was significantly associated with region of the world, with the highest in western Europe and the lowest in Asia (Table S1 and Figure 1). The countries with highest caffeine intake were Turkey, the Netherlands, and the United Kingdom, and those with the lowest intake were China, Peru, and Spain (Table S2).

Figure 1
Median caffeinated beverages consumption in cups per week according to regions of the world.

Predictors of Caffeinated Beverage Intake

Table 1 shows baseline characteristics by caffeine consumption (caffeine drinkers versus nondrinkers). Among other differences, patients who drank caffeine at baseline were younger and more often male and white and had higher body mass index and higher prevalence of hypercholesterolemia, smoking, multivessel CAD, and heart failure but lower prevalence of diabetes mellitus. Table S3 shows the same characteristics considering the safety population.

Table 1
Baseline Characteristics According to Baseline Caffeine Intake (Intention‐to‐Treat Database, N = 9694)

Risk of Dyspnea With Ticagrelor

The risk of dyspnea due to ticagrelor has been described previously. 5 There was a significant increase in dyspnea compared with placebo use with both ticagrelor doses. This increase was consistent for the incidence of any dyspnea throughout trial follow‐up and for dyspnea leading to drug discontinuation (Figure 2). Rates of dyspnea reporting had wide variability among regions of the world, with western Europe and North America being more likely to report dyspnea than South America, eastern Europe, and Asia/Pacific (Table S4).

Figure 2
Proportion of patients with dyspnea according to randomized groups.

P values are shown for comparison of proportions across the 3 groups for each adverse event.

---

### P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome [^115EKLXN]. The Annals of Pharmacotherapy (2011). Low credibility.

Acute coronary syndrome (ACS) is a continuum of disease that includes non-ST-segment elevation ACS and ST-segment elevation myocardial infarction. The purpose of this article is to define the developing role of ticagrelor in ACS and compare it to currently available P2Y₁₂ receptor inhibitors. While clopidogrel remains the "workhorse" P2Y₁₂ receptor inhibitor for many patients with ACS and prasugrel has an established role in select situations, clinicians must now assimilate the evolving role of ticagrelor. Although ticagrelor offers important advances in the management of ACS (eg, reversibility), there are also notable clinical considerations (eg, unique adverse effects such as dyspnea). Based on the current evidence, we propose an algorithm to aid clinicians in the selection of a P2Y₁₂ receptor inhibitor for patients with ACS in various clinical situations.

---

### Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial [^1163q3us]. Journal of the American Heart Association (2015). Low credibility.

Dyspnea‐Related Outcomes, Discontinuation of Study Drug, and Adverse Events

Ticagrelor significantly increased the incidence of dyspnea, both in patients with and without COPD (Figure 1). Although absolute dyspnea event rates were higher in COPD patients, ticagrelor‐associated relative risks were similar and no COPD status‐by‐treatment interaction was found (P = 0.616). Dyspnea‐related discontinuation of study drug was more common with ticagrelor, irrespective of COPD status. COPD patients treated with ticagrelor showed numerically more dyspnea‐related events leading to discontinuation of study drug compared to non‐COPD patients (2.5% vs. 0.9%), although the numbers of discontinuations were very small. Overall premature discontinuation of study drug was more common in COPD patients treated with ticagrelor (Table 2).

Table 2
Randomized Treatment Use and Dyspnea‐Related AEs

Adherence to study drug, defined as the use of more than 80% of the study medication during each interval between visits, was slightly higher in COPD patients treated with ticagrelor, whereas the exposure, meaning total days on treatment, was slightly lower. There were more adverse events (AEs) related to dyspnea in patients with COPD treated with ticagrelor (Table 2). The numbers of serious AEs (SAEs) were small. The suspected etiologies of dyspnea events are shown in Table S2.

Subgroup Analyses

Efficacy and safety outcomes in subgroups defined by initial treatment approach (invasive investigation vs. medically managed) were consistent with the main findings (data not shown). Likewise, an additional analysis with nonsmokers excluded was also consistent with the main findings (data not shown).

---

### Premature ticagrelor discontinuation in Secondary prevention of atherosclerotic CVD: JACC review topic of the week [^113xeL5W]. Journal of the American College of Cardiology (2019). Medium credibility.

Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^115w8L1E]. Journal of the American Heart Association (2020). Medium credibility.

Conclusions

In high‐risk patients with prior MI taking ticagrelor for secondary prevention, intake of caffeinated beverages at baseline compared with no intake was not associated with lower rates of dyspnea due to ticagrelor. Caffeine consumption in the range occurring in this cohort appeared to be safe, with no excess of ischemic cardiovascular events, arrhythmias, or sudden cardiac death. These findings do not support a recommendation of drinking caffeine to improve drug tolerability related to dyspnea, and they challenge the hypothesis that dyspnea induced by ticagrelor is mediated mainly by adenosine.

---

### Ticagrelor [^114vo3uY]. FDA (2025). Medium credibility.

5.1 Risk of Bleeding

Drugs that inhibit platelet function including ticagrelor increase the risk of bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)].

Patients treated for acute ischemic stroke or TIA

Patients at NIHSS > 5 and patients receiving thrombolysis were excluded from THALES and use of ticagrelor in such patients is not recommended.

5.2 Discontinuation of Ticagrelor in Patients Treated for Coronary Artery Disease

Discontinuation of ticagrelor will increase the risk of myocardial infarction, stroke, and death in patients being treated for coronary artery disease. If ticagrelor must be temporarily discontinued (e.g., to treat bleeding or for significant surgery), restart it as soon as possible. When possible, interrupt therapy with ticagrelor for five days prior to surgery that has a major risk of bleeding. Resume ticagrelor as soon as hemostasis is achieved.

5.3 Dyspnea

In clinical trials, about 14% (PLATO and PEGASUS) to 21% (THEMIS) of patients treated with ticagrelor developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment but led to study drug discontinuation in 0.9% (PLATO), 1.0% (THALES), 4.3% (PEGASUS), and 6.9% (THEMIS) of patients.

In a substudy of PLATO, 199 subjects underwent pulmonary function testing irrespective of whether they reported dyspnea. There was no indication of an adverse effect on pulmonary function assessed after one month or after at least 6 months of chronic treatment.

If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to ticagrelor, no specific treatment is required; continue ticagrelor without interruption if possible. In the case of intolerable dyspnea requiring discontinuation of ticagrelor, consider prescribing another antiplatelet agent.

5.4 Bradyarrhythmias

Ticagrelor can cause ventricular pauses [see Adverse Reactions (6.1)]. Bradyarrhythmias including AV block have been reported in the post-marketing setting. Patients with a history of sick sinus syndrome, 2ndor 3rddegree AV block or bradycardia-related syncope not protected by a pacemaker were excluded from clinical studies and may be at increased risk of developing bradyarrhythmias with ticagrelor.

---

### 2025 ACC / AHA / ACEP / NAEMSP / SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^115PWRrv]. Circulation (2025). High credibility.

Oral P2Y12 inhibitor characteristics and supportive trial considerations include the following: Clinically available oral P2Y12 inhibitors include clopidogrel, prasugrel, and ticagrelor; clopidogrel is the least potent oral P2Y12 inhibitor and requires more time to reach its maximal platelet inhibition after a loading dose; ticagrelor and prasugrel are more potent than clopidogrel and achieve more rapid onset of inhibition of platelet activation but with increased risk of bleeding compared with clopidogrel; ticagrelor may cause subjective transient dyspnea in approximately 10% to 15% of patients after ACS; several trials have demonstrated the clinical benefit of oral P2Y12 inhibitors in ACS for reducing MACE but with increased risk of bleeding; in patients with STEMI treated with fibrinolytic therapy, the addition of clopidogrel to aspirin reduces 30-day MACE, including recurrent MI, and improves survival; and dose reduction of prasugrel should be considered in patients ≥ 75 years of age and in those with a body weight < 60 kg.

---

### Review of the ticagrelor trials evidence base [^112GLUMe]. Journal of the American Heart Association (2024). Medium credibility.

The US Food and Drug Administration approved package insert states that ticagrelor is superior to clopidogrel for at least the first 12 months following ACS based on the PLATO trial, a statement supported by clinical practice guidelines. Compared with patients enrolled in clinical trials, however, patients treated in clinical practice have higher risk for ischemic and bleeding events and more comorbidities. Although an initial observational reportpublished in 2009 supported the PLATO trial results, several subsequent observational reports from more contemporary population cohorts in the Netherlands, China, Canada, Sweden, the United States and Korea, and Englandhave shown similar efficacy with increased bleeding and dyspnea rates for ticagrelor compared with clopidogrel. These studies have the usual observational trial limitations of residual confounding, inaccurate ascertainment of events, and miscoding, but do not have the limitation of selection bias associated with randomized trials and they reached the same conclusion with different study designs. In the PLATO trial, only 60% of patients underwent PCI, 40% with bare metal stents and 60% with first generation stents. In the current era, ischemic risk including stent thrombosis is lower due to advances in stent technology (biocompatible or no polymers, improved anti‐proliferative drugs, thinner stent struts, better delivery platforms), stent implantation optimization with intracoronary imaging, and advances in guideline‐directed medical therapy for secondary prevention. Therefore, bleeding avoidance strategies associated with DAPT have become increasingly important and have changed the balance between ischemic benefit and bleeding risk that determines net clinical benefit for different antiplatelet strategies. Additionally, compared with clopidogrel, the observational outcome reports may have been influenced by increased rates of ticagrelor discontinuation that have been noted in most studies and explained by patient complaints about increased bleeding and dyspnea side effects, inconvenient twice daily administration, and the increased cost of therapy (clopidogrel and prasugrel are generic drugs).

---

### Ticagrelor [^113E9kaY]. FDA (2025). Medium credibility.

6.2 Post-marketing Experience

The following adverse reactions have been identified during post-approval use of ticagrelor. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: Thrombotic Thrombocytopenic Purpura (TTP) has been rarely reported with the use of ticagrelor. TTP is a serious condition which can occur after a brief exposure (< 2 weeks) and requires prompt treatment.

Immune system disorders: Hypersensitivity reactions including angioedema [see Contraindications (4.3)].

Respiratory Disorders: Central sleep apnea, Cheyne-Stokes respiration

Skin and subcutaneous tissue disorders: Rash

---

### Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial [^111JZHEw]. Journal of the American Heart Association (2015). Low credibility.

Introduction

Patients with chronic obstructive pulmonary disease (COPD) are at high risk of experiencing acute coronary syndromes (ACS). 1 This high risk is partly attributed to shared common risk factors, such as higher age, smoking, 2 and systemic inflammation. 3 In addition, reduced pulmonary function, independent of smoking, has been associated with increased risk of ACS, arrhythmias, and cardiovascular death. 4, 5, 6, 7 Patients with COPD experiencing ACS have subsequent increased risk of recurrent ischemic events and increased all‐cause mortality compared to those without COPD. 8, 9, 10, 11 This is, to a certain extent, explained by comorbidities, 11 but it has been shown that patients with COPD are less likely to receive reperfusion therapy and guideline‐recommended secondary prevention therapies, which could further worsen long‐term outcomes. 8, 9, 11, 12

The PLATO study showed superior efficacy of the nonthienopyridine platelet P2Y₁₂–receptor inhibitor, ticagrelor, as compared to clopidogrel in preventing death from vascular causes, myocardial infarction (MI), or stroke in patients with ACS, without an increase in overall major bleeding events. 13 However, patients randomized to ticagrelor had increased incidence of dyspnea, a known adverse effect commonly characterized as mild to moderate and often transient without being associated with either differences in efficacy or safety outcomes 14 or an adverse effect on pulmonary function. 15 Previous substudies from PLATO have shown ticagrelor to be superior to clopidogrel in different high‐risk patient populations, including patients with diabetes 16 or impaired renal function, 17 and in the elderly. 18

Despite ACS patients with concomitant COPD being at higher risk thus warranting efficacious therapies, clinicians may be reluctant to prescribe ticagrelor to these patients owing to the increased incidence of dyspnea. At the time the PLATO trial was published, an accompanying editorial discouraged the use of ticagrelor in patients with COPD. 19 Furthermore, the European Medicines Agency assessment report indicates caution when prescribing ticagrelor to patients with history of COPD, owing to a potentially increased absolute risk of dyspnea. 20 Thus, the aim of the present study was to study the efficacy and safety profile of ticagrelor versus clopidogrel in ACS patients with COPD.

---

### Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial [^1168T2Ae]. JAMA Cardiology (2016). Medium credibility.

Importance

In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death, myocardial infarction, or stroke by 15% to 16% among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo.

Objective

To investigate the reasons and timing of discontinuation of treatment with ticagrelor among stable patients prior myocardial infarction.

Design, Setting, and Participants

In the PEGASUS-TIMI 54 trial, 21 162 stable outpatients with prior myocardial infarction were randomly assigned to 90 mg of ticagrelor twice daily, 60 mg of ticagrelor twice daily, or placebo, with all of the patients receiving a low dose of aspirin. These participants were followed up for a median of 33 months (study start date: October 2010; completion date: December 2014). Discontinuation of treatment was evaluated by treatment arm, cause, and timing. This analysis was initiated in May 2015.

Main Outcome and Measure

Discontinuation of treatment.

Results

Over 33 months, 32%, 29%, and 21% of patients receiving 90 mg of ticagrelor, 60 mg of ticagrelor, and placebo, respectively, discontinued treatment (P < .001). Discontinuation of treatment due to an adverse event occurred in 19%, 16%, and 9% of patients, respectively (P < .001). The most frequent adverse events leading to discontinuation of treatment were bleeding (with Kaplan-Meier event rates of 7.8%, 6.2%, and 1.5% of patients, respectively; P < .001) and dyspnea (6.5%, 4.6%, and 0.8% of patients, respectively; P < .001). Eighty-six percent of bleeding events that led to the discontinuation of treatment with ticagrelor were nonmajor, and 86% of adverse events due to dyspnea that led to discontinuation of treatment with ticagrelor were mild or moderate in severity. The discontinuation rates are annualized for patients who received 90 mg of ticagrelor twice daily (hazard ratio [HR], 2.00 [95% CI, 1.84–2.16] for the first year; HR, 1.12 [95% CI, 1.00–1.26] for the second and third years) and patients who received 60 mg of ticagrelor twice daily (HR, 1.59 [95% CI, 1.46–1.73] for the first year; HR, 1.18 [95% CI, 1.06–1.32] for the second and third years) compared with patients who received placebo.

Conclusions and Relevance

When initiated among stable patients with prior myocardial infarction, discontinuation of treatment with ticagrelor was driven primarily by nonserious adverse events occurring primarily early after randomization. For patients completing 1 year of treatment, the subsequent discontinuation rate was low. These data demonstrate how adverse events considered "nonserious" by traditional trial criteria may have an effect on quality of life and, thus, may precipitate the discontinuation of treatments and underscore the need for patient education and counseling on the timing and nature of adverse effects with the aim of improving adherence when appropriate.

Trial Registration

clinicaltrials.gov Identifier: NCT01225562.

---

### Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial [^116NwAmN]. Journal of the American Heart Association (2015). Low credibility.

Background

Patients with chronic obstructive pulmonary disease experiencing acute coronary syndromes are at high risk for clinical events. In the Platelet Inhibition and Patient Outcomes trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke afterbut increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor frompatients.

Methods and Results

In 18 624 patients withrandomized to treatment with ticagrelor or clopidogrel, history ofwas recorded in 1085 (5.8%). At 1 year, the primary endpoint occurred in 17.7% of patients withversus 10.4% in those without(P < 0.001). The 1‐year event rate for the primary endpoint inpatients treated with ticagrelor versus clopidogrel was 14.8% versus 20.6% (hazard ratio = 0.72; 95% confidence interval: 0.54 to 0.97), for death from any cause 8.4% versus 12.4% (= 0.70; 95%: 0.47 to 1.04), and for‐defined major bleeding rates at 1 year 14.6% versus 16.6% (= 0.85; 95%: 0.61 to 1.17). Dyspnea occurred more frequently with ticagrelor (26.1% vs. 16.3%; = 1.71; 95%: 1.28 to 2.30). There was no differential increase in the relative risk of dyspnea compared to non‐patients (1.85). Nostatus‐by‐treatment interactions were found, showing consistency with the main trial results.

Conclusions

In this post‐hoc analysis, patients experienced high rates of ischemic events. Ticagrelor versus clopidogrel reduced and substantially decreased the absolute risk of ischemic events (5.8%) inpatients, without increasing overall major bleeding events. The benefit‐risk profile supports the use of ticagrelor in patients withand concomitant.

Clinical Trial Registration

Unique identifier:00391872.

---

### Design and rationale of TROCADERO: a TRial of caffeine to alleviate dyspnEa related to ticagrelOr [^114LNQyX]. American Heart Journal (2015). Low credibility.

Background

Ticagrelor treatment has the side effect of increased incidence of dyspnea. Adenosine-induced dyspnea is augmented by ticagrelor and can be alleviated with the adenosine antagonist theophylline. Caffeine is a closely related xanthine derivative.

Objectives

The primary objective of the TROCADERO is to evaluate the effect of caffeine versus placebo on ticagrelor-associated dyspnea, measured by the visual analog scale area under the curve in patients with ongoing ticagrelor treatment after an acute coronary syndrome event.

Design

After a run-in period of 1 to 7 days of absence of caffeine intake, acute coronary syndrome patients with ticagrelor-induced dyspnea (planned inclusion 416) are randomized in a blinded fashion to either caffeine 200 mg twice daily or matching placebo with a treatment duration of 1 week. The primary efficacy end point is change in visual analog scale area under the curve for dyspnea, and the primary safety end point is occurrence of high on-treatment platelet reactivity measured by the VerifyNow P2Y12 assay.

Conclusions

This trial will determine if adenosine antagonism by caffeine can alleviate ticagrelor-related dyspnea, without impairing the antiplatelet effect of ticagrelor.

---

### Platelet inhibition, endothelial function, and clinical outcome in patients presenting with ST-Segment-elevation myocardial infarction randomized to ticagrelor versus prasugrel maintenance therapy: long-term follow-up of the REDUCE-MVI trial [^115A6xYw]. Journal of the American Heart Association (2020). Medium credibility.

Patient Symptoms and Clinical Outcome

A well‐known drug‐specific side effect of ticagrelor unrelated to pulmonary function is the manifestation of dyspnea. 43, 44 We demonstrated a 42% occurrence of dyspnea in the ticagrelor group versus 35% in the prasugrel group (nonsignificant relative difference of 17%) and a similar severity of dyspnea at 1 year. Although most patients in our study were revascularized at 1‐month follow‐up, we know that (microvascular) angina still occurs in about 40%. 45 We hypothesized that ticagrelor could improve (microvascular) angina by its previously discussed off‐target properties. In our study, we did not observe between‐group differences in the presence or severity of angina pectoris or heart failure.

In our study, despite limited statistical power, MACE (9% in the ticagrelor group versus 14% in the prasugrel group) and the occurrence of bleeding (47% in the ticagrelor group versus 63% in the prasugrel group) at long‐term follow‐up were not statistically different in patients randomized to ticagrelor versus prasugrel. This was in line with a previous observational study in 318 patients with STEMI with the combined end point of major adverse cardiac and cerebrovascular events at 1‐year follow‐up. 46 As our study was not powered to detect differences in clinical end points, caution is needed interpreting our results. The TRITON‐TIMI‐38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38) showed that prasugrel compared with clopidogrel prevents ischemic events in patients with ACS, but this resulted in an accompanying increase in Thrombolysis in Myocardial Infarction major bleedings. 47 The PLATO (Platelet Inhibition and Patient Outcomes) trial demonstrated a similar benefit of ticagrelor over clopidogrel with regard to the occurrence of ischemic events in patients with ACS, but without an increase in Thrombolysis in Myocardial Infarction major bleeding rate. 48 On the other hand, it has been reported that patients with STEMI randomized to ticagrelor have an increased risk of bleeding compared with prasugrel. 46 The ISAR‐REACT‐5 trial including 41.1% STEMI, 46.2% non‐ST‐segment‐elevation myocardial infarction (NSTEMI), and 12.7% unstable angina patients demonstrated reduced occurrence of MACE without a difference in major bleeding in the prasugrel versus ticagrelor group in a modified intention‐to‐treat analysis. 27

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^116bejsi]. Journal of the American Heart Association (2020). Medium credibility.

Ticagrelor is a potent reversible P2Y₁₂ inhibitor that reduces ischemic risk in patients with acute coronary syndromes 1 and in those who need long‐term secondary prevention after myocardial infarction (MI). 2 Dyspnea associated with ticagrelor has been described as an adverse event of mild to moderate intensity that is generally self‐limited and not associated with any adverse cardiovascular or pulmonary impact. 3, 4 The potential adverse impact of dyspnea, however, is that it may affect drug adherence, particularly when initiated in stable asymptomatic patients. 5 Therefore, strategies to improve drug tolerability and reduce discontinuation due to dyspnea may be clinically useful.

Although it is well documented that dyspnea while taking ticagrelor is not associated with disturbed heart or lung function, its exact mechanism remains unclear. Ticagrelor has been shown to inhibit ENT‐1 (equilibrative nucleoside transporter 1) in red blood cells and thus decrease adenosine reuptake. 6, 7 Therefore, it is hypothesized that higher adenosine exposure due to ticagrelor could account for dyspnea and for other drug‐related adverse events, such as ventricular pauses and gout. 8 In contrast, other reports have challenged whether inhibition of adenosine uptake could lead to increase in adenosine blood levels of clinical relevance. 9, 10 In the HIGH‐TECH (Hunting for the Off‐Target Properties of Ticagrelor on Endothelial Function in Humans) trial, investigators did not find increased levels of plasma adenosine among patients experiencing dyspnea while on ticagrelor. 10 Consequently, other pathways involved in dyspnea may exist as alternative explanations for this adverse event, for example, a direct effect of ticagrelor on P2Y₁₂ receptors from inhibitory neuron fibers that convey dyspnea signaling. 11, 12

---

### The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient outcomes (PLATO) trial [^116PXu6s]. European Heart Journal (2014). Low credibility.

Consistent with the main study data, ticagrelor was associated with an increase in non-CABG-related major bleeding when compared with clopidogrel in both women [adjusted HR: 1.19 (0.90−1.56)] and men [adjusted HR: 1.37 (1.10−1.72); Figure 2]. There was no significant interaction between treatment and sex (P = 0.42; Figure 2).

Additional analyses of the associations between sex, randomized treatment, and either final diagnosis or planned treatment also revealed no significant interactions for the bleeding endpoints (interaction P -value range: 0.17−0.67).

Higher rates of dyspnoea were reported during ticagrelor treatment than with clopidogrel treatment in both women [16.3 vs. 9.0%; HR: 1.86 (1.58−2.20)] and men [KM estimate at 1 year: 14.2 vs. 8.3%; HR: 1.81 (1.62−2.01); Table 2]. Ventricular pauses were more frequent in patients receiving ticagrelor compared with those receiving clopidogrel; however, a significant difference in rates was only observed for pauses of ≥ 3 s during the first week in men [6.0 vs. 3.7%; HR: 1.64 (1.09−2.47)]. There was no evidence of interaction between randomized treatment and sex for dyspnoea and ventricular pauses (interaction P -value range: 0.34−0.89).

Table 2
The incidence of dyspnoea and ventricular pauses by sex and treatment

---

### Ticagrelor to reduce myocardial injury in Patients with high-risk coronary artery plaque [^1139ANqU]. JACC: Cardiovascular Imaging (2020). Medium credibility.

Safety outcomes

There were no suspected unexpected serious adverse reactions over the course of the study. Serious adverse events occurred in 7 (7%) of 100 patients who received at least 1 single dose of ticagrelor and 15 (11.9%) of 101 patients who were administered placebo (Supplemental Table 3). There were no reported major life-threatening or other major bleeding events over the course of the study. Minimal bleeding events (bruising) were reported in 64 (64.0%) patients in the ticagrelor group and 12 (11.9%) patients in the placebo group (Supplemental Table 4). Dyspnea episodes occurred in 24 (24%) patients in the ticagrelor group compared with 8 (7.9%) patients in the placebo group at 1 year.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^113uQECS]. Journal of the American Heart Association (2020). Medium credibility.

Discussion

The current study describes important findings. First, caffeinated beverages are routinely ingested by high‐risk patients with prior MI, but this habit is highly correlated with region and comorbidities. Second, compared with no caffeine intake, caffeine intake was not associated with lower rates of dyspnea in patients with prior MI taking ticagrelor for secondary prevention, and the increase in dyspnea with ticagrelor versus placebo, at both doses, was not modified by baseline caffeine intake Third, caffeine does not appear to be associated with higher risk of ischemic cardiovascular events or clinically important arrythmias in patients with previous MI and high‐risk features.

Overall, we found that the majority of patients (> 75%) in the almost 10 000‐patient cohort consumed at least 1 cup of caffeinated beverage per week. We observed important regional variation, and the overall patterns matched those described in other studies. 20, 21 Moreover, similar to prior reports, caffeine intake was associated with smoking and obesity. 17

When ticagrelor first became available, dyspnea was a troubling side effect. Even though it was shown to be benign, it may prompt patients to stop treatment prematurely. Adenosine exposure has been postulated as a possible cause of this dyspnea, and ticagrelor has been shown to reduce adenosine uptake by red blood cells and to increase plasma concentrations. 6 However, mechanistic studies linking this increase in adenosine to dyspnea have shown conflicting results. In a study with healthy volunteers, van den Berg et al 22 could not find any increase in ex vivo adenosine reuptake at relevant plasma concentrations of ticagrelor. In addition, the STEEL‐PCI (Study of Two Doses of Ticagrelor in Percutaneous Coronary Intervention) study did not detect any effect of ticagrelor 60 or 90 mg on adenosine uptake in patients with stable CAD, raising the question of whether therapeutic concentrations of ticagrelor are sufficient to affect adenosine metabolism to a clinically relevant extent. 9 Finally, the HI‐TECH study aimed to analyze possible pleiotropic effects from ticagrelor in a population with acute coronary syndromes. The investigators could not find any association between dyspnea with ticagrelor use and adenosine plasma levels; however, ticagrelor plasma concentrations were significantly higher in those patients experiencing dyspnea. 10 These findings suggest that adenosine exposure does not account for most dyspnea induced by ticagrelor and raise the possibility of other explanations for this adverse reaction, for example, a direct P2Y 12 inhibitory effect on the central nervous system. 11

---

### Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: understanding and addressing the global risk-treatment paradox [^115abCSt]. Clinical Cardiology (2019). Medium credibility.

Table 3
Summary of the quality indicators: definitions and support from guidelines

Figure 2
Association between the European Society of Cardiology Acute Cardiovascular Care Association quality indicators for acute myocardial infarction and crude 30‐day mortality. Adapted from Bebb et al. 72 The composite opportunity QI was divided into the following categories: zero, received no interventions out of those eligible for; low, received < 40% of interventions eligible for; intermediate, received ≥ 40% to < 80% of interventions eligible for; and high, received ≥ 80% of interventions eligible for. Abbreviations: ACEI; angiotensin‐converting enzyme inhibitor; ARB; angiotensin receptor blocker; BB, β‐blocker; CI, confidence interval; DAPT, dual antiplatelet therapy; EF, ejection fraction; HF, heart failure; LV, left ventricular; NSTEMI, non‐ST‐segment elevation myocardial infarction; PCI, percutaneous coronary intervention; QI, quality indicator; STEMI, ST‐segment elevation myocardial infarction

Guidelines and hospital protocols should emphasize the importance of documenting patient history, which could affect NSTEMI diagnosis, and of regularly assessing the risks and benefits of therapies to suit the patient's clinical status, which may change over time. 54 Furthermore, guidelines and protocols should include guidance on how to manage patients with dyspnea because some physicians are concerned about dyspnea related to ticagrelor use in their patients, given that dyspnea is more frequently reported in patients with ACS prescribed ticagrelor compared with clopidogrel. 73, 74 The incidence of dyspnea in a real‐world setting has been shown to be greater than that reported in clinical trials and may lead to higher rates of ticagrelor discontinuation. 74 However, given that there is evidence to suggest that dyspnea can resolve during inhibitor use, only in the case of persistent ticagrelor‐related dyspnea should drug discontinuation be considered. 73

---

### 2025 ACC / AHA / ACEP / NAEMSP / SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^111u3uNH]. Journal of the American College of Cardiology (2025). High credibility.

Oral P2Y12 inhibitors — Clinically available oral P2Y12 inhibitors include clopidogrel, prasugrel, and ticagrelor; clopidogrel is the least potent oral P2Y12 inhibitor and requires more time to reach its maximal platelet inhibition after a loading dose because it requires biotransformation in the liver to form its active metabolite. Ticagrelor and prasugrel are more potent than clopidogrel and achieve more rapid onset of inhibition of platelet activation but with increased risk of bleeding compared with clopidogrel. Ticagrelor may cause subjective transient dyspnea in approximately 10% to 15% of patients after acute coronary syndromes (ACS). In patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy, the addition of clopidogrel to aspirin reduces 30-day major adverse cardiovascular events (MACE), including recurrent myocardial infarction, and improves survival. In a secondary analysis of TRITON-TIMI 38, subgroup analyses using an outcome of net clinical benefit demonstrated net harm with prasugrel versus clopidogrel among patients with previous transient ischemic attack or stroke; dose reduction of prasugrel should be considered in patients ≥ 75 years of age and in those with a body weight < 60 kg.

---

### Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial [^117DfPYC]. Journal of the American Heart Association (2015). Low credibility.

Background

Patients with chronic obstructive pulmonary disease (COPD) experiencing acute coronary syndromes (ACS) are at high risk for clinical events. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients.

Methods and Results

In 18 624 patients with ACS randomized to treatment with ticagrelor or clopidogrel, history of COPD was recorded in 1085 (5.8%). At 1 year, the primary endpoint occurred in 17.7% of patients with COPD versus 10.4% in those without COPD (P < 0.001). The 1-year event rate for the primary endpoint in COPD patients treated with ticagrelor versus clopidogrel was 14.8% versus 20.6% (hazard ratio [HR] = 0.72; 95% confidence interval [CI]: 0.54 to 0.97), for death from any cause 8.4% versus 12.4% (HR = 0.70; 95% CI: 0.47 to 1.04), and for PLATO-defined major bleeding rates at 1 year 14.6% versus 16.6% (HR = 0.85; 95% CI: 0.61 to 1.17). Dyspnea occurred more frequently with ticagrelor (26.1% vs. 16.3%; HR = 1.71; 95% CI: 1.28 to 2.30). There was no differential increase in the relative risk of dyspnea compared to non-COPD patients (HR = 1.85). No COPD status-by-treatment interactions were found, showing consistency with the main trial results.

Conclusions

In this post-hoc analysis, COPD patients experienced high rates of ischemic events. Ticagrelor versus clopidogrel reduced and substantially decreased the absolute risk of ischemic events (5.8%) in COPD patients, without increasing overall major bleeding events. The benefit-risk profile supports the use of ticagrelor in patients with ACS and concomitant COPD.

Clinical Trial Registration

URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872.

---

### Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the bern percutaneous coronary intervention registry [^1169tAzL]. Circulation: Cardiovascular Interventions (2018). Low credibility.

Background

Although ticagrelor has improved clinical outcomes among patients with acute coronary syndrome compared with clopidogrel, adherence to this new antiplatelet agent in real-world practice has not been fully investigated.

Methods and Results

Between November 2011 and June 2014, 1278 of 4831 consecutive patients (26.5%) undergoing percutaneous coronary intervention at a tertiary care center were treated with ticagrelor. Premature ticagrelor cessation was categorized into (1) change, when ticagrelor was replaced by prasugrel; (2) de-escalation, when ticagrelor was replaced by clopidogrel; and (3) premature discontinuation, when ticagrelor was discontinued without P2Y12 inhibitor replacement. Of 1278 patients treated with ticagrelor, premature treatment cessation occurred in 212 patients (17%). De-escalation to clopidogrel was the most frequent scenario (57%; n = 120), followed by premature discontinuation (28%; n = 60) and change to prasugrel (15%; n = 32). Reasons for ticagrelor cessation included adverse effects (49%), initiation of oral anticoagulation (19%), and unspecified general practitioner preference (10%). Most frequent adverse effects leading to premature ticagrelor cessation were bleeding (41%), dyspnea (29%), and gastrointestinal symptoms (18%). Premature ticagrelor cessation was not associated with an increased risk of cardiac death, myocardial infarction, or stroke (hazard ratio, 0.73; 95% confidence interval: 0.40–1.32; P = 0.29).

Conclusions

Premature ticagrelor cessation in routine clinical practice occurred in 1 of 6 patients and was primarily related to adverse effects among which bleeding and dyspnea were the most frequent. Although premature ticagrelor cessation was not associated with adverse cardiovascular outcomes, this finding requires careful interpretation in view of the modest sample size.

Clinical Trial Registration

URL: https://www.clinicaltrials.gov. Unique identifier: NCT02241291.

---

### Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial [^114dZzQL]. Circulation: Cardiovascular Quality and Outcomes (2012). Low credibility.

Background

Elderly patients with acute coronary syndrome are at high risk of recurrent ischemic events and death, and for both antithrombotic therapy and catheter-based complications. This prespecified analysis investigates the effect and treatment-related complications of ticagrelor versus clopidogrel in elderly patients (≥ 75 years of age) with acute coronary syndrome compared with those < 75 years of age.

Methods and Results

The association between age and the primary composite outcome, as well as major bleeding were evaluated in the PLATelet inhibition and patient Outcomes (PLATO) trial using Cox proportional hazards. Similar models were used to evaluate the interaction of age with treatment effects. Hazard ratios were adjusted for baseline characteristics. The clinical benefit of ticagrelor over clopidogrel was not significantly different between patients aged ≥ 75 years of age (n = 2878) and those < 75 years of age (n = 15 744) with respect to the composite of cardiovascular death, myocardial infarction, or stroke (interaction P = 0.56), myocardial infarction (P = 0.33), cardiovascular death (P = 0.47), definite stent thrombosis (P = 0.81), or all-cause mortality (P = 0.76). No increase in PLATO-defined overall major bleeding with ticagrelor versus clopidogrel was observed in patients aged ≥ 75 years (hazard ratio, 1.02; 95% confidence interval, 0.82–1.27) or patients aged < 75 years (hazard ratio, 1.04; 95% confidence interval, 0.94–1.15). Dyspnea and ventricular pauses were more common during ticagrelor than clopidogrel treatment, with no evidence of an age-by-treatment interaction.

Conclusions

The significant clinical benefit and overall safety of ticagrelor compared with clopidogrel in acute coronary syndrome patients in the PLATO cohort were not found to depend on age.

---

### Review of the ticagrelor trials evidence base [^117CpcUN]. Journal of the American Heart Association (2024). Medium credibility.

Acute Coronary Syndromes

DAPT with clopidogrel compared with aspirin monotherapy was initially shown to reduce the risk of major adverse cardiovascular events in patients after non–ST‐segment elevation ACS in the CURE trial, but with increased risk of major and minor bleeding. DAPT with prasugrel in the TRITON‐TIMI 38 trialand ticagrelor in the PLATO trialsubsequently was shown to further reduce the risk of major adverse cardiovascular events, but with the risk of additional increased major and minor bleeding.

Comparison of Ticagrelor With Clopidogrel

The US Food and Drug Administration first approved ticagrelor in July 2011 to reduce the risks of cardiovascular death and MI in patients with ACS based on results from the PLATO trial that compared DAPT with ticagrelor or clopidogrel (Table 2). The benefit of ticagrelor over clopidogrel in the composite primary outcome of cardiovascular death, MI, or stroke at 12 months was present with or without ST‐segment elevation and with or without percutaneous coronary intervention (PCI). Additionally, the risk of stent thrombosis was reduced and there was a surprising reduction in cardiovascular death, a finding that has not been reproduced in any other DAPT trial. Further analysis showed no difference in stroke rates. Maintenance doses of aspirin above 100 mg were associated with decreased ticagrelor effectiveness in a prespecified subgroup analysis, one potential explanation for the lack of benefit in patients enrolled in North America where aspirin doses were high, but the biological significance of the putative interaction remains unexplained, so chance alone cannot be excluded. There was no increased risk of PLATO major bleeding with ticagrelor, but there were increased rates of major and minor bleeding in patients not undergoing coronary artery bypass graft surgery (CABG) and in dyspnea.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^111HbJag]. Journal of the American Heart Association (2020). Medium credibility.

Study Limitations

This study has several important limitations. First, caffeine intake was recorded only at baseline, so it is possible that caffeine ingestion could have changed during trial follow‐up. Second, we could not ascertain caffeine intake from all patients from the trial because this hypothesis was raised after enrollment started. Nevertheless, baseline clinical characteristics were well matched between those from the main trial population and the almost 10 000 patients included in this analysis. 2 Nevertheless, it is not known whether the implementation of this substudy while the trial was ongoing could have influenced our results. For example, knowing the hypothesis that caffeine intake could mitigate dyspnea induced by ticagrelor may have influenced site investigators to stop the study drug less commonly among caffeine drinkers than among nondrinkers, thus explaining a spurious association between caffeine drinking and lower rates of drug discontinuation due to dyspnea but without any association between drinking caffeine and overall dyspnea rates. Third, we did not collect detailed information regarding each type of caffeinated beverage. It is well known that the concentrations of caffeine, as well as roasting properties and other characteristics, differ substantially among different beverages, so we cannot be sure that our results would be applicable to different sources of caffeine. Fourth, dyspnea was investigator‐reported and not centrally adjudicated, and sites were not required to perform extensive diagnostic workup to rule out other potential causes. Finally, even with adjusted models, the findings should be viewed as only hypothesis‐generating given the nonrandomized design of the analysis and the lack of adjustment for multiplicity. Especially regarding the lower rates of MACE with caffeine, future randomized studies should clarify this question because in an observational study, uncontrolled unknown confounders may explain most of the association.

---

### Efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention: a meta-analysis [^115sbStH]. Clinical Pharmacology and Therapeutics (2021). Medium credibility.

Interestingly, short‐term DAPT followed by ticagrelor monotherapy significantly decreased all‐cause mortality compared with standard DAPT, which may be due to the accompanying decreased risk of major bleeding. Further studies investigating the particular concept of P2Y 12 inhibitor/ticagrelor monotherapy are needed to underscore and confirm this result. Indeed, the reduction of major bleeding following PCI is an important clinical aim, due to its strong association with mortality. All three trials, in this analysis compared short‐term DAPT followed by ticagrelor monotherapy to standard DAPT. Conceivably, it is easier to demonstrate less bleeding with a single antiplatelet therapy regimen than with a DAPT regimen, and our meta‐analysis confirmed the significant reduction of major bleeding events with short‐term DAPT followed by ticagrelor monotherapy compared with standard DAPT.

In contrast, short‐term DAPT followed by ticagrelor monotherapy was associated with an unchanged relative risk of MACE compared with standard DAPT, even showing a trend toward fewer events in the ticagrelor monotherapy treatment group, which makes it an attractive and feasible treatment option in the future. This is further substantiated by the significant results in favor of short‐term DAPT followed by ticagrelor monotherapy in our net clinical benefit analysis (Figure 1b).

Compared with ticagrelor monotherapy, aspirin monotherapy may have similar efficacy in reducing bleeding events, with potentially no increased risk of MACE. Each of the three clinical trials fall short of a duly needed third study arm, investigating the effects of short‐term DAPT followed by aspirin monotherapy. The head‐to‐head comparison of short‐term DAPT followed by aspirin vs. P2Y₁₂ inhibitor (ticagrelor in particular) monotherapy is, however, missing. Given the relatively inexpensive costs of aspirin compared with ticagrelor and increased risk of discontinuation due to side effects, such as dyspnea, a three‐way study design would be of major interest. Two studies, the RESETand the OPTIMIZEtrials, have investigated the concept of short‐term DAPT (1–3 months) followed by aspirin monotherapy vs. standard DAPT (6–12 months). Both studies used zotarolimus‐eluting stents only and found no change in ischemic and bleeding risk between groups.

---

### Real-world evidence on disparities on the initiation of ticagrelor versus prasugrel in patients with acute coronary syndrome [^116PBR2V]. Journal of the American Heart Association (2023). Medium credibility.

Limitations

The study is an observational single‐center study and was neither planned nor powered to provide information on efficacy or safety of antiplatelet or anticoagulation regimens in clinical routine.

First, most information on the presence or absence of label restrictions had to be collected from electronic archives where all available information was screened by health care professionals (ie, cardiologists in training and licensed study nurses) using predefined criteria for noneligibility. Therefore, we cannot fully exclude human errors leading to a systematic underestimation of eligibility for either drug due to incomplete collection of exclusion criteria or adverse events.

Second, we assessed the eligibility of prasugrel and ticagrelor at presentation and during the short hospital stay, but we did not monitor patients for the postacute development of new high‐degree atrioventricular block, ventricular pauses, or sick sinus syndrome, or for the occurrence of relevant dyspnea requiring temporal or permanent discontinuation of ticagrelor, increase of uric acid, or worsening of renal function during therapy with ticagrelor. In regard to the warning of ticagrelor in patients with chronic kidney injury or hemodialysis, we decided to include these patients in our analysis as eligible for ticagrelor, because data show an increased usage of ticagrelor in these patient cohorts.

---

### Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial [^115uEGZ6]. Journal of the American Heart Association (2015). Low credibility.

Conclusions

Patients with ACS and concomitant COPD are a high‐risk population with a worse ischemic outcome as well as increased bleeding rates. Ticagrelor significantly reduced the risk of ischemic events with an absolute reduction in COPD patients that was nearly 4 times as great as in non‐COPD patients, without an increase in overall major bleeding. There was no differential increase in the relative risk of dyspnea compared to non‐COPD patients, but the increase in absolute risk was greater in COPD patients. Although a post‐hoc analysis, the benefit‐risk profile supports the use of ticagrelor in patients with ACS and COPD. In consideration of the accumulated evidence that patients with COPD constitute a high‐risk population with a poor prognosis, who may also be undertreated with guideline‐recommended secondary prevention, ticagrelor presents an opportunity to improve outcomes in patients with ACS and COPD.

---

### Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention [^11116F3R]. JAMA Internal Medicine (2020). High credibility.

Importance

Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased bleeding and dyspnea.

Objective

To compare the risk of MACE with ticagrelor vs clopidogrel in patients with ACS treated with percutaneous coronary intervention (PCI), to compare major bleeding and dyspnea, and to evaluate the association between P2Y12 inhibitor adherence and MACE.

Design, Setting, and Participants

Population-based cohort study using data of patients discharged alive after PCI for ACS from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry from April 1, 2012, to March 31, 2016, with follow-up to 1 year. Analysis began April 2018.

Exposures

Outpatient prescription for ticagrelor or clopidogrel within 31 days after PCI. Adherence was defined as a medication refill adherence value of 80% or higher.

Main Outcomes and Measures

Major adverse coronary events, a composite of all-cause death, hospitalization for ACS, unplanned coronary revascularization, or stent thrombosis within 365 days after index PCI. Secondary outcomes included hospitalization for major bleeding and emergency department visit for dyspnea.

Results

Of 11 185 individuals who underwent PCI, the median (interquartile range) age was 61 (54–71) years, and 2760 (24.7%) were women. Ticagrelor users (4076 [36.4%]) were generally younger and had fewer cardiac and noncardiac comorbidities than clopidogrel users. Ticagrelor was not associated with lower risk of MACE (adjusted hazard ratio [aHR], 0.97; 95% CI, 0.85–1.10); however, it was associated with an increased risk of major bleeding (aHR, 1.51; 95% CI, 1.29–1.78) and dyspnea (aHR, 1.98; 95% CI, 1.47–2.65). A total of 3328 ticagrelor users (81.6%) were adherent during the study vs 5256 of clopidogrel users (73.9%) (P < .001; χ² = 86.4). In the full cohort, adherence was associated with a lower MACE risk (aHR, 0.79; 95% CI, 0.69–0.90 for adherence of ≥ 80% vs < 80%). Differences in other secondary outcomes were not statistically significant. Sensitivity and subgroup analyses were consistent with primary analyses.

Conclusions and Relevance

In this population-based cohort study of patients with ACS who underwent PCI, outpatient use of ticagrelor was not associated with a statistically significant reduction in MACE vs clopidogrel; however, it was associated with more major bleeding and dyspnea.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^116LhADd]. Journal of the American Heart Association (2020). Medium credibility.

In our study, caffeine intake was not associated with lower rates of dyspnea on ticagrelor, but surprisingly, there appeared to be an association with lower rates of drug discontinuation due to dyspnea. If adenosine were the predominant pathway involved in ticagrelor‐induced dyspnea, then we would expect to observe consistently lower rates of overall dyspnea among caffeine drinkers and not only an effect on the decision to stop the drug prematurely. Together with the fact that severe and moderate dyspnea intensities were not lower with caffeine, this may suggest that lower rates of drug discontinuation due to dyspnea could be explained by play of chance, bias (eg, knowing that caffeine could potentially reduce dyspnea could have made the study investigators stop the study drug less frequently among caffeine drinkers), or other unknown uncontrolled confounder. The null association between caffeine drinking and dyspnea while taking ticagrelor in our study is in accordance with the results from the HI‐TECH study and reinforces that other alternative explanations may exist for dyspnea induced by ticagrelor besides increase in adenosine exposure. 10, 11

Other reports have described improvements in dyspnea with ticagrelor when intravenous theophylline or aminophylline was used, 15, 23 although one was a single case report and the other evaluated dyspnea induced during adenosine infusion (and not necessarily caused only by ticagrelor). That caffeine could achieve the same effect is plausible, considering that, like theophylline derivatives, caffeine blocks adenosine‐mediated effects. 14 This hypothesis was of sufficient importance to drive a randomized trial that would rigorously investigate the impact of caffeine on dyspnea related to ticagrelor. 24 Unfortunately, the trial enrolled only 23 patients out of a calculated sample size of 416. However, none of the randomized patients benefited from the administration of caffeine 200 mg twice a day (a higher amount than is usually found in a single cup of coffee, which is 60–90 mg), and the results of a preliminary questionnaire survey among 180 patients with ticagrelor‐induced dyspnea revealed that caffeine failed to improve dyspnea in 153 of 173 patients who responded. 25

---

### Ticagrelor (Brilinta) [^114ugKUf]. FDA (2024). Medium credibility.

Unknown frequency adverse reactions associated with the use of ticagrelor PO (also known as Brilinta) include: angioedema, apnea, atrioventricular block, cheyne-Stokes breathing, skin rash and thrombotic thrombocytopenic purpura.

---

### Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention [^116W1cCE]. JAMA (2020). Excellent credibility.

Importance

Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine practice merits attention.

Objective

To determine the association of ticagrelor vs clopidogrel with ischemic and hemorrhagic events in patients undergoing percutaneous coronary intervention (PCI) for ACS in clinical practice.

Design, Setting, and Participants

A retrospective cohort study of patients with ACS who underwent PCI and received ticagrelor or clopidogrel was conducted using 2 United States electronic health record-based databases and 1 nationwide South Korean database from November 2011 to March 2019. Patients were matched using a large-scale propensity score algorithm, and the date of final follow-up was March 2019.

Exposures

Ticagrelor vs clopidogrel.

Main Outcomes and Measures

The primary end point was net adverse clinical events (NACE) at 12 months, composed of ischemic events (recurrent myocardial infarction, revascularization, or ischemic stroke) and hemorrhagic events (hemorrhagic stroke or gastrointestinal bleeding). Secondary outcomes included NACE or mortality, all-cause mortality, ischemic events, hemorrhagic events, individual components of the primary outcome, and dyspnea at 12 months. The database-level hazard ratios (HRs) were pooled to calculate summary HRs by random-effects meta-analysis.

Results

After propensity score matching among 31 290 propensity-matched pairs (median age group, 60–64 years; 29.3% women), 95.5% of patients took aspirin together with ticagrelor or clopidogrel. The 1-year risk of NACE was not significantly different between ticagrelor and clopidogrel (15.1% [3484/23 116 person-years] vs 14.6% [3290/22 587 person-years]; summary HR, 1.05 [95% CI, 1.00–1.10]; p = 0.06). There was also no significant difference in the risk of all-cause mortality (2.0% for ticagrelor vs 2.1% for clopidogrel; summary HR, 0.97 [95% CI, 0.81–1.16]; p = 0.74) or ischemic events (13.5% for ticagrelor vs 13.4% for clopidogrel; summary HR, 1.03 [95% CI, 0.98–1.08]; p = 0.32). The risks of hemorrhagic events (2.1% for ticagrelor vs 1.6% for clopidogrel; summary HR, 1.35 [95% CI, 1.13–1.61]; p = 0.001) and dyspnea (27.3% for ticagrelor vs 22.6% for clopidogrel; summary HR, 1.21 [95% CI, 1.17–1.26]; P < .001) were significantly higher in the ticagrelor group.

Conclusions and Relevance

Among patients with ACS who underwent PCI in routine clinical practice, ticagrelor, compared with clopidogrel, was not associated with significant difference in the risk of NACE at 12 months. Because the possibility of unmeasured confounders cannot be excluded, further research is needed to determine whether ticagrelor is more effective than clopidogrel in this setting.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^114Qa6pJ]. Journal of the American Heart Association (2020). Medium credibility.

Background

A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Because caffeine is an adenosine antagonist, it can potentially improve drug tolerability with regard to dyspnea. Furthermore, association between caffeine and cardiovascular events is of clinical interest.

Methods and Results

This prespecified analysis used data from the54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54) trial, which randomized 21 162 patients with prior myocardial infarction to ticagrelor 60 mg or 90 mg or matching placebo (twice daily). Baseline caffeine intake in cups per week was prospectively collected for 9694 patients. Outcomes of interest included dyspnea, major adverse cardiovascular events (ie, the composite of cardiovascular death, myocardial infarction, or stroke), and arrhythmias. Dyspnea analyses considered the pooled ticagrelor group, whereas cardiovascular outcome analyses included patients from the 3 randomized arms. After adjustment, caffeine intake, compared with no intake, was not associated with lower rates of dyspnea in patients taking ticagrelor (adjusted hazard ratio (HR), 0.91; 95%, 0.76–1.10; P = 0.34). There was no excess risk with caffeine for major adverse cardiovascular events (adjusted HR, 0.78; 95% CI, 0.63–0.98; P = 0.031), sudden cardiac death (adjusted HR, 0.98; 95% CI, 0.57–1.70; P = 0.95), or atrial fibrillation (adjusted odds ratio, 1.07; 95% CI, 0.56–2.04; P = 0.84).

Conclusions

In patients taking ticagrelor for secondary prevention after myocardial infarction, caffeine intake at baseline was not associated with lower rates of dyspnea compared with no intake. Otherwise, caffeine appeared to be safe in this population, with no apparent increase in atherothrombotic events or clinically significant arrhythmias.

Registration

:; Unique identifier:01225562.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^112fJy5i]. Journal of the American Heart Association (2020). Medium credibility.

Relationship Between Caffeine Intake and Dyspnea in Patients Taking Ticagrelor

At univariate analysis, in the pooled ticagrelor group, caffeine drinkers had similar rates of dyspnea compared with nondrinkers and numerically lower rates of drug discontinuation due to dyspnea. After adjustment, caffeine intake was not associated with lower rates of overall dyspnea (adjusted hazard ratio [HR], 0.91; 95% CI, 0.76–1.10; P = 0.34). Similarly, there was no association with lower rates of mild dyspnea (adjusted HR, 0.97; 95% CI, 0.76–1.24; P = 0.78; Table 2). Although there was a significant association between drinking caffeine and lower rates of drug discontinuation due to dyspnea (adjusted HR, 0.72; 95% CI, 0.53–0.98; P = 0.035), there was no significant association with lower rates of moderate dyspnea (adjusted HR, 0.84; 95% CI, 0.63–1.14; P = 0.27) or moderate to severe dyspnea (adjusted HR, 0.82; 95% CI, 0.62–1.08; P = 0.16; Table 2 and Figure 3). Table S5 shows the same results for each separate ticagrelor dose and for the placebo group. Table S6 shows those results stratified by regions of higher versus lower caffeine intake.

Table 2
Association Between Caffeine Intake at Baseline and Dyspnea Adverse Events in Patients Taking Ticagrelor, Pooled Dose Groups (n = 6363)

Figure 3
Association between dyspnea and baseline caffeine intake in the pooled ticagrelor group (n = 6363).

Adjusted for age, sex, race, body mass index, hypercholesterolemia, heart failure, diabetes mellitus, presence of multivessel coronary artery disease history of percutaneous coronary intervention, type of qualifying myocardial infarction (ST‐segment–elevation myocardial infarction vs non–ST‐segment–elevation myocardial infarction), glomerular filtration rate < 60 mL/min per 1.73 m², smoking, region of the world, and use of angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers at baseline. Adjindicates adjusted hazard ratio.

---

### Ticagrelor (Brilinta) [^111FAcH4]. FDA (2025). Medium credibility.

5.1 Risk of Bleeding

Drugs that inhibit platelet function including BRILINTA increase the risk of bleeding [see Warnings and Precautions

(5.2) and Adverse Reactions (6.1)].

Patients treated for acute ischemic stroke or TIA

Patients at NIHSS > 5 and patients receiving thrombolysis were excluded from THALES and use of BRILINTA in such patients is not recommended.

5.2 Discontinuation of BRILINTA in Patients Treated for Coronary Artery Disease

Discontinuation of BRILINTA will increase the risk of myocardial infarction, stroke, and death in patients being treated

for coronary artery disease. If BRILINTA must be temporarily discontinued (e.g., to treat bleeding or for significant

surgery), restart it as soon as possible. When possible, interrupt therapy with BRILINTA for five days prior to surgery that

has a major risk of bleeding. Resume BRILINTA as soon as hemostasis is achieved.

5.3 Dyspnea

In clinical trials, about 14% (PLATO and PEGASUS) to 21% (THEMIS) of patients treated with BRILINTA developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment but led to study drug discontinuation in 0.9% (PLATO), 1.0% (THALES), 4.3% (PEGASUS), and 6.9% (THEMIS) of patients.

In a substudy of PLATO, 199 subjects underwent pulmonary function testing irrespective of whether they reported dyspnea. There was no indication of an adverse effect on pulmonary function assessed after one month or after at least 6 months of chronic treatment.

If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to BRILINTA, no specific treatment is required; continue BRILINTA without interruption if possible. In the case of intolerable dyspnea requiring discontinuation of BRILINTA, consider prescribing another antiplatelet agent.

5.4 Bradyarrhythmias

BRILINTA can cause ventricular pauses [see Adverse Reactions (6.1)]. Bradyarrhythmias including AV block have been

reported in the postmarketing setting. Patients with a history of sick sinus syndrome, 2ndor 3rddegree AV block or

bradycardia-related syncope not protected by a pacemaker were excluded from clinical studies and may be at increased

risk of developing bradyarrhythmias with ticagrelor.

---

### Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial [^1132TSUW]. Journal of the American Heart Association (2015). Low credibility.

Methods

The PLATO trial (identifier: NCT00391872) enrolled 18 624 patients between October 2006 and July 2008. Details about the study design, patients, outcome definitions, and results have been published. 13, 21 In each country, the study was approved by national regulatory authorities and by local ethics committees or institutional review boards, according to local regulations. All patients provided written consent to participate in the study. Patients were eligible for enrollment if they were hospitalized for ACS, with or without ST‐segment elevation, and with symptom onset during the previous 24 hours. Major exclusion criteria were contraindication to clopidogrel, fibrinolytic therapy within 24 hours before randomization, a need for oral anticoagulation therapy, an increased risk of bradycardia, and simultaneous therapy with a strong cytochrome P450 3A inhibitor or inducer. Patients were randomized to ticagrelor or clopidogrel in a double‐blind, double‐dummy fashion. All patients received acetylsalicylic acid unless intolerant. The median treatment duration was 9.1 months.

The primary efficacy endpoint was time to first occurrence of any event from the composite endpoint consisting of death from vascular causes, MI, or stroke. Secondary efficacy endpoints were individual events of MI, stroke, death from vascular causes, and death from any cause. The primary safety endpoint was time to first occurrence of major bleeding, defined by the study criteria. In addition, bleeding events defined according to the TIMI criteria, and life‐threatening or fatal bleeding (defined by the study criteria) were also assessed. Other adverse events, including dyspnea, were recorded in the electronic case report form. Each on‐site investigator assessed COPD status at the time of randomization and reported in the case report form whether the patient had "current COPD" or "no COPD".

---

### Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and patient outcomes [PLATO] pulmonary function substudy) [^115K7U4T]. The American Journal of Cardiology (2011). Low credibility.

The Platelet Inhibition and Patient Outcomes (PLATO) trial showed that ticagrelor reduced the risk for cardiovascular events in patients with acute coronary syndromes compared to clopidogrel but was associated with increased incidence of dyspnea. This substudy assessed whether ticagrelor affects pulmonary function in patients with acute coronary syndromes: 199 patients enrolled in the PLATO trial and receiving randomized treatment with ticagrelor 90 mg twice daily (n = 101) or clopidogrel 75 mg/day (n = 98) took part in the pulmonary function substudy. Patients with advanced lung disease, congestive heart failure, or coronary artery bypass graft surgery after the index event were excluded. Pulse oximetry (blood oxygen saturation), spirometry (forced expiratory volume in 1 second, forced vital capacity, and forced expiratory flow between 25% and 75% of forced vital capacity before and 20 minutes after inhalation of a β₂ agonist), lung volumes (total lung capacity, functional residual capacity, residual volume), and diffusion capacity were performed after patients received study medication for 30 to 40 days. Tests were then repeated < 10 days before and approximately 30 days after the discontinuation of study medication. After a mean treatment duration of 31 days, there were no differences between the groups for any of the pulmonary function parameters. At the end of treatment (mean 211 days) and after the discontinuation of study medication (mean 32 days after the last dose), there was also no evidence of a change in pulmonary function in either group. For example, forced expiratory volume in 1 second values before β(2) agonist inhalation in the ticagrelor and clopidogrel groups were 2.81 ± 0.73 and 2.70 ± 0.84 L, respectively, at the first visit and did not change significantly at subsequent visits. In conclusion, no effect of ticagrelor on pulmonary function was seen in this cohort of patients with acute coronary syndromes compared to clopidogrel.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^11299R9y]. Journal of the American Heart Association (2020). Medium credibility.

This current analysis in almost 10 000 high‐risk patients with prior MI did not find any association between caffeinated beverage intake and higher rates of cardiovascular events. Other studies in patients with prior MI have similarly found no suggestion of harm from coffee or other caffeine sources when prospective cohort reports were considered; however, many of these studies were limited to a single country, were not representative of modern medical therapy, or had lower risk cohorts. 17, 26, 27, 28 Our findings of lower rates of MACE are reassuring because they likely exclude an excess risk of cardiovascular atherothrombotic events with the ingestion of caffeine, even considering a population with prior MI and high‐risk features such as those patients enrolled in the PEGASUS TIMI 54 trial. If one considers the upper boundary of the 95% CI for the adjusted HR for MACE with caffeine in our study, a 30% increase in the relative risk can be ruled out. This margin of noninferiority is in accordance with what has been used in trials with antidiabetic drugs. 29 The limb outcomes, although not significantly lower, were directionally consistent with overall MACE and MI reductions. In addition, drinking caffeine was associated with numerically higher rates of TIMI major bleeding. Caffeine is known to decrease platelet aggregation by upregulation of the adenosine A₂ receptor on platelets, so those observations could have biological plausibility. 30 This hypothesis should be investigated in future randomized event‐driven studies.

We did not find any association between caffeine consumption and clinically relevant arrhythmias. Regarding atrial fibrillation, such concerns have been raised in the past, 31 although more recent reports have been reassuring. 32 However, no data specifically in the particular group of patients with prior MI has been published to date. Regarding potentially fatal arrhythmias, extremely high doses of intravenous caffeine can provoke malignant ventricular arrhythmias in experimental models, 33 and high coffee intake has been associated with sudden cardiac death in prior reports. 16 In our data, incidence of sudden cardiac death was not higher with caffeine. Despite the apparent absence of higher risk of arrhythmias with caffeine intake in our study, given the small number of events and the wide CIs (for which the upper boundary of the CI for the adjusted HR does not exclude an acceptable risk of 1.3), we cannot completely rule out such a risk. Moreover, we cannot exclude the possibility that drinks with high caffeine concentrations are harmful to patients with CAD because we have not specifically addressed this type of beverage.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^114mXyur]. Journal of the American Heart Association (2020). Medium credibility.

The primary analysis for this article was the incidence of dyspnea among patients assigned to ticagrelor during the trial, with additional analyses for drug discontinuation due to dyspnea and for dyspnea according to different intensities. Dyspnea was reported by study sites using standard safety reporting processes, with dyspnea intensity reported as mild, moderate, or severe, according to the site investigator's assessment. As has been reported previously, dyspnea was considered to have led to drug discontinuation when it was the main cause of study drug withdrawal, and this definition excluded discontinuation in the setting of an efficacy event. 5

The cardiovascular outcome analyses considered MACE (the composite of cardiovascular death, MI, or stroke) and its individual components, all‐cause mortality, death due to CAD, sudden cardiac death, clinically relevant arrhythmias, major bleeding as defined by Thrombolysis in Myocardial Infarction (TIMI), and major adverse limb events (MALE). All deaths, bleeding, and cardiovascular events, except arrhythmias and MALE, were independently adjudicated by a clinical events committee whose members were unaware of study drug assignment but not necessarily blinded to information regarding caffeine intake. Arrhythmias were site‐reported using standard safety reporting. Event terms were searched for arrhythmias of special interest including atrial fibrillation or flutter, ventricular tachycardia or fibrillation, and other tachyarrhythmias. Narratives from the serious adverse events were reviewed independently by 2 authors (R.H.M.F. M.P.B.) to ascertain whether arrhythmias consistent with one of those categories were present, with disagreements resolved by consensus. MALE, the composite of acute limb ischemia or peripheral revascularization for ischemia, were prospectively collected and blindly reviewed, as defined previously. 19

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^111nYe3U]. Journal of the American Heart Association (2020). Medium credibility.

Background A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Because caffeine is an adenosine antagonist, it can potentially improve drug tolerability with regard to dyspnea. Furthermore, association between caffeine and cardiovascular events is of clinical interest. Methods and Results This prespecified analysis used data from the PEGASUS TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) trial, which randomized 21 162 patients with prior myocardial infarction to ticagrelor 60 mg or 90 mg or matching placebo (twice daily). Baseline caffeine intake in cups per week was prospectively collected for 9694 patients. Outcomes of interest included dyspnea, major adverse cardiovascular events (ie, the composite of cardiovascular death, myocardial infarction, or stroke), and arrhythmias. Dyspnea analyses considered the pooled ticagrelor group, whereas cardiovascular outcome analyses included patients from the 3 randomized arms. After adjustment, caffeine intake, compared with no intake, was not associated with lower rates of dyspnea in patients taking ticagrelor (adjusted hazard ratio (HR), 0.91; 95% CI, 0.76–1.10; P = 0.34). There was no excess risk with caffeine for major adverse cardiovascular events (adjusted HR, 0.78; 95% CI, 0.63–0.98; P = 0.031), sudden cardiac death (adjusted HR, 0.98; 95% CI, 0.57–1.70; P = 0.95), or atrial fibrillation (adjusted odds ratio, 1.07; 95% CI, 0.56–2.04; P = 0.84). Conclusions In patients taking ticagrelor for secondary prevention after myocardial infarction, caffeine intake at baseline was not associated with lower rates of dyspnea compared with no intake. Otherwise, caffeine appeared to be safe in this population, with no apparent increase in atherothrombotic events or clinically significant arrhythmias. Registration URL: https://www.clini​caltr​ials.gov; Unique identifier: NCT01225562.

---

### Ticagrelor: oral reversible P2Y₁₂ receptor antagonist for the management of acute coronary syndromes [^113atjsJ]. Clinical Therapeutics (2012). Low credibility.

Background

The clinical benefits of dual antiplatelet treatment (aspirin + clopidogrel) in the management of acute coronary syndromes (ACS) are well established. However, clopidogrel is a prodrug that requires hepatic activation. Concerns regarding its delayed onset of action, variability in antiplatelet effects, and prolonged recovery of platelet function after discontinuation have prompted the development of P2Y₁₂ receptor antagonists. Ticagrelor is the most recently developed P2Y₁₂ receptor antagonist available in the United States. Ticagrelor is a nonthienopyridine antiplatelet agent and is the first reversible oral antagonist of the P2Y₁₂ receptors.

Objective

This article reviews the pharmacology, clinical efficacy, and tolerability of ticagrelor use in management of ACS.

Methods

Peer-reviewed clinical trials, review articles, and relevant treatment guidelines published from 1966 to March 15, 2012, were identified from the MEDLINE and Current Content databases using the search terms ticagrelor, ACS, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and cost-effectiveness. Citations from available articles were also reviewed for additional references.

Results

Nine pharmacokinetics/pharmacodynamics studies in humans and 1 clinical study were identified. In addition, the findings from 6 subanalyses based on the clinical study were included. Compared with clopidogrel, ticagrelor was associated with a significantly reduced composite rate of death from cardiovascular causes, myocardial infarction, or stroke (ticagrelor, 9.8%; clopidogrel, 11.7%; hazard ratio [HR] = 0.84; 95% CI, 0.77–0.92; P < 0.001). The difference in the rates of major bleeding was not significant (ticagrelor, 11.6%; clopidogrel, 11.2%). Ticagrelor was associated with a higher rate of non-coronary artery bypass graft surgery related major bleeding (4.5% vs 3.8%; P = 0.03), including fatal intracranial bleeding (0.1% vs 0.01%; P = 0.02), and fewer cases of other types of fatal bleeding (0.1% vs 0.3%; P = 0.03). Other adverse events reported with ticagrelor use included dyspnea (13.8%), headache (6.5%), and bradyarrhythmia (5.8%). The effects of ticagrelor have not been compared to those of other antiplatelet agents, including prasugrel.

Conclusions

Based on the findings from the present review, ticagrelor provides reversible inhibition of adenosine diphosphate-induced platelet aggregation, with a faster onset of action than clopidogrel, and is effective in the treatment of patients with ACS. More data are required to definitively position ticagrelor with respect to other antiplatelet agents, including prasugrel.

---

### Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event [^114Q7Zhz]. BMJ Case Reports (2021). High credibility.

Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding. We present a case of 70-year-old woman who developed diarrhoea following initiation of DAPT comprising of aspirin and ticagrelor following PCI. After excluding more common causes, it was attributed to ticagrelor administration and completely resolved after it was replaced with another oral antiplatelet agent. On follow-up, the patient reported complete resolution of symptoms.

---

### Caffeinated beverage intake, dyspnea with ticagrelor, and cardiovascular outcomes: insights from the PEGASUS-TIMI 54 trial [^114ncsYp]. Journal of the American Heart Association (2020). Medium credibility.

Caffeine and theophylline are adenosine antagonists that can block adenosinergic A₁A receptors involved in the mediation of dyspnea by pulmonary C‐fibers. 13, 14 In healthy volunteers, ticagrelor enhanced dyspnea intensity during adenosine infusion, an effect that was decreased by intravenous theophylline. 15 If dyspnea induced by ticagrelor is mostly caused by adenosine, then it is plausible that caffeine intake may also attenuate the intensity of this adverse event and improve drug tolerability.

Because of its stimulant effects, the potential risks and benefits of caffeine in high‐risk patients with coronary artery disease (CAD) continue to be debated. Some reports have raised concerns about higher risk of sudden death with coffee intake by individuals with prior CAD. 16 Conversely, other reports have observed an inverse association between coffee intake and cardiovascular risk. 17 To date, there has not been an evaluation of caffeinated beverage intake and adjudicated cardiovascular outcomes in a large, well‐characterized, multinational cohort of high‐risk patients with prior MI receiving current optimal medical therapy.

We sought to investigate 2 hypotheses: (1) that the risk of dyspnea with ticagrelor would be affected by baseline intake of caffeinated beverages and (2) that caffeine intake would not be associated with any excess risk of major adverse cardiovascular events (MACE) or arrhythmias in a high‐risk population of patients with prior MI.

---

### Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction [^114GubKU]. Clinical Cardiology (2021). Medium credibility.

2.4 Results of 6‐month follow‐up

The incidence of MACE was similar between the two groups of patients for 6 months of follow‐up (all p > .05). There were decreasing trends in the incidences of minimal bleeding event, minor bleeding event, dyspnea, and gout in the LD group (all p > .05) (Table 4).

TABLE 4
Results of 6‐month follow‐up

---

### Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish coronary angiography and angioplasty registry [^111sCHid]. Journal of the American Heart Association (2020). Medium credibility.

Why our results differ from the PLATO trial may be explained by the following features. While in PLATO more than one third of patients were treated conservatively, all patients in our study were treated with PCI. Compared with our study, patients in PLATO were younger and more frequently men which confirms well‐known discrepancies between randomized clinical trials and unselected patient populations. 26 Consequently, based on the established predictors for bleeding, 27, 28 our unselected population may have been more prone to bleeding when exposed to a potent antiplatelet agent. Indeed, the increased risk of bleeding may constitute mediating pathway 29 for the observed absence of mortality benefit with ticagrelor in an unselected population. 8, 9 Another simple but potent mediator for attenuation of ticagrelors' efficacy outside randomized clinical trial may be decreased compliance because of the higher rate of adverse events (dyspnea, bleeding), administration of the drug twice per day and higher costs. Indeed, in the PLATO trial, ticagrelor had higher discontinuation rate than clopidogrel with 23% of patients being non‐compliant. It seems reasonable to argue that non‐compliance with ticagrelor is even higher outside the settings of well‐controlled clinical trial and with a different (more non‐compliant prone) patient population.

---

### Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial [^111z7Qzt]. BMJ (2019). Excellent credibility.

Discussion

Principal findings

This PRINCE trial results indicated that the proportion of high platelet reactivity at 90 days reduced with ticagrelor compared with clopidogrel, in patients with acute minor stroke and those at moderate-to-high risk of transient ischaemic attack treated with aspirin. This trial was not powered to study clinical events. However, we observed fewer strokes and composite outcomes at 90 days in patients who were treated with dual antiplatelet therapy using ticagrelor/aspirin compared with clopidogrel/aspirin within 24 hours of the onset of minor stroke or transient ischaemic attack, without increasing the risk of major, minor, or intracranial haemorrhage. Treatment discontinuation was, however, higher with ticagrelor due to an increased rate of dyspnoea and minimal haemorrhagic events (that is, epistaxis).

Comparison with other studies

The major haemorrhage rate in the present study was lower than that found in the PLATO study (ticagrelor/aspirin group 1.5% v 11.6%; clopidogrel/aspirin group 1.2% v 11.2%). This difference could be partly due to the short term use of dual antiplatelet therapy in our study compared with the PLATO study (21 v 277 days). By contrast, a slightly higher major haemorrhagic rate was found in PRINCE than in the Asian subgroup in the SOCRATES trial (1.5% in the ticagrelor/aspirin group in PRINCE v 0.6% in the ticagrelor used as monotherapy in SOCRATES). This difference could be related to the combined use of two drugs in our study. Similar to that reported in the PLATO and SOCRATES trials, dyspnoea occurred more commonly with ticagrelor than with clopidogrel treatment.

---

### Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist [^115kjYMd]. The Annals of Pharmacotherapy (2010). Low credibility.

Objective

To summarize the pharmacokinetic and pharmacodynamic properties of ticagrelor, a selective P2Y12 receptor antagonist, and evaluate its role in the treatment of patients with acute coronary syndromes (ACS).

Data Sources

A literature search was conducted in MEDLINE (1966-November 2009), International Pharmaceutical Abstracts (1970-November 2009), and EMBASE (1990-November 2009) using the MeSH terms and key words AZD6140, ticagrelor, P2Y12 receptor antagonist, cardiovascular disease, ACS, atherothrombosis, and platelets.

Study Selection and Data Extraction

Selected studies evaluated the pharmacology, pharmacokinetics, pharmacodynamics, safety, and efficacy of ticagrelor for the treatment of ACS.

Data Synthesis

Ticagrelor selectively and reversibly blocks the P2Y12 receptor, inhibiting platelet aggregation and preventing amplification of platelet activation. Optimal dosing strategy as determined by ticagrelor's pharmacokinetic and pharmacodynamic profile is a loading dose of 180 mg followed by 90 mg by mouth twice daily. At these doses, greater platelet inhibition is observed with ticagrelor as compared to clopidogrel 75 mg once daily in both clopidogrel-experienced and -naïve patients. Studies in patients experiencing ACS concluded that ticagrelor reduced the rate of cardiovascular death, nonfatal myocardial infarction, stent thrombosis, and overall mortality compared to clopidogrel without increasing major bleeding when administered with standard therapy for ACS. There was no significant difference in the risk of stroke with ticagrelor compared to clopidogrel; however, intracranial bleeding was more common with ticagrelor. Ticagrelor is well tolerated; however, minor bleeding, dyspnea, hypotension, nausea, and ventricular pauses were reported more frequently than with clopidogrel. Reversible inhibition with ticagrelor may allow for more rapid surgical intervention after discontinuation, suggesting greater flexibility in treatment of ACS.

Conclusions

Ticagrelor's improved pharmacokinetic and pharmacodynamic profile builds upon the limitations of currently available P2Y12 receptor antagonists. Ticagrelor represents a promising approach for the prevention of cardiovascular events in patients with ACS.

---

### Novel antiplatelet therapies for atherothrombotic diseases [^115PMYXG]. Arteriosclerosis, Thrombosis, and Vascular Biology (2019). Medium credibility.

The role of ticagrelor monotherapy among patients with PAD was assessed in the EUCLID study (Examining Use of Ticagrelor in Peripheral Artery Disease), which did not demonstrate a significant improvement in the composite primary outcome of CV death, MI, or ischemic stroke compared with clopidogrel. Ticagrelor monotherapy for nonsevere ischemic stroke or high-risk TIA was assessed in the international SOCRATES study (Acute Stroke or Transient Ischaemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) and did not demonstrate a significant reduction in time to occurrence of stroke, MI, or death within 90 days compared with aspirin. Combination therapy with ticagrelor and aspirin for acute ischemic stroke or TIA is being evaluated in the THALES trial (Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and Aspirin for Prevention of Stroke or Death;. Unique identifier: NCT03354429). The role of ticagrelor monotherapy compared with aspirin after PCI with a drug-eluting stent is being evaluated in the TWILIGHT (Ticagrelor with Aspirin or Along in High-Risk Patients After Coronary Intervention) and TICO (Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome;. Unique identifier: NCT02494895) studies.

There has additionally been interest in leveraging potential off-target effects of ticagrelor and other antiplatelet agents. However, a recent study of the effects of ticagrelor, prasugrel, and clopidogrel on endothelial function and vascular biomarkers found no difference in the reactive hyperemia index or biomarker levels in a population of post-ACS patients treated with the various agents. Additionally, the study found no evidence that ticagrelor increases plasma adenosine levels compared with other antiplatelet agents, although this has been previously implicated as a mechanism to explain ticagrelor related side effects, including bradycardia and dyspnea.

Overall, current evidence supports ticagrelor as a first line agent for ACS with or without PCI in addition to aspirin, and for long term therapy among patients with a history of MI, assuming they are at low bleeding risk. The role of ticagrelor as an adjunct to aspirin in patients with stroke or PAD is uncertain, and the role of ticagrelor monotherapy in patients with CAD remains under investigation.

---

### Ticagrelor [^114ScKsd]. FDA (2025). Medium credibility.

6 ADVERSE REACTIONS

The following adverse reactions are also discussed elsewhere in the labeling:

Bleeding [see Warnings and Precautions (5.1)]
Dyspnea [see Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Ticagrelor has been evaluated for safety in more than 58,000 patients.

Bleeding in PLATO (Reduction in risk of thrombotic events in ACS)

Figure 1 is a plot of time to the first non-CABG major bleeding event.

Figure 1: Kaplan-Meier estimate of time to first non-CABG PLATO-defined major bleeding event (PLATO)

Frequency of bleeding in PLATO is summarized in Tables 1 and 2. About half of the non-CABG major bleeding events were in the first 30 days.

Table 1: Non-CABG related bleeds (PLATO)

No baseline demographic factor altered the relative risk of bleeding with ticagrelor compared to clopidogrel.

In PLATO, 1,584 patients underwent CABG surgery. The percentages of those patients who bled are shown in Figure 2 and Table 2.

Figure 2: 'Major fatal/life-threatening' CABG-related bleeding by days from last dose of study drug to CABG procedure (PLATO)

---

### Ticagrelor-associated shift from obstructive to central sleep apnea: a case report [^116A5CJv]. Journal of Clinical Sleep Medicine (2019). Medium credibility.

None

Ticagrelor, a P2Y12 receptor antagonist, is used in combination with aspirin in patients with coronary artery disease. Recent reports suggest that ticagrelor might induce central sleep apnea (CSA) by increasing chemosensitivity to hypercapnia. We herein describe the case of a patient with positive airway pressure (PAP)-treated obstructive sleep apnea (OSA), in whom PAP-telemonitoring revealed the emergence of CSA and Cheyne-Stokes respiration (CSR) after initiation of ticagrelor for an acute coronary syndrome with preserved left ventricular ejection fraction. Ticagrelor-associated shift from OSA to CSA was confirmed by respiratory polygraphy after PAP withdrawal, and was associated with an increased chemosensitivity to hypercapnia. Ticagrelor discontinuation was associated with the recurrence of pure OSA and the normalization of hypercapnic ventilatory response. A transient recurrence of CSA and CSR was identified by PAP-telemonitoring after accidental reintroduction of the drug. Further studies are required to determine the mechanisms, incidence, and consequences of ticagrelor-associated CSA.

Citation

Paboeuf C, Priou P, Meslier N, Roulaud F, Trzepizur W, Gagnadoux F. Ticagrelor-associated shift from obstructive to central sleep apnea: a case report. J Clin Sleep Med. 2019;15(8):1179–1182.

---

### Using ticagrelor to prevent recurrent type 1 and type 2 myocardial infarctions: boon or bane? [^111WE5Wg]. Journal of the American Heart Association (2018). Low credibility.

Given that the benefit of ticagrelor was restricted to reducing type 1 MIs, clinicians may ask: How effective was ticagrelor? Confining the analysis to relative measures, such as HRs, tends to produce a distorted sense of proportion and makes it difficult to translate the results into clinical practice. Using absolute event rates gives clinicians a better sense of what works in cardiovascular medicine. 10 If it is assumed that the treatment effect is consistent from one year to the next, the absolute differences in annual event rates can be used to calculate the numbers needed to treat. 11 Comparing numbers needed to treat for 2° prevention (Table) reveals that using ticagrelor is on par with using aspirin for secondary prevention, 12 high‐intensity compared with low‐intensity statins to prevent nonfatal MI, 13 or the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor arilocumab to prevent recurrent MI. 14 Because the benefit of ticagrelor was confined to type 1 MIs, it can be shown that 461 (95% CI, 280–2617) must be treated with ticagrelor to prevent a single type 1 MI, and ≈700 patients (95% CI, 516–1267 patients) must be treated each year to prevent a single ST‐segment–elevation MI.

Table 1
NNTs per Year to Prevent Recurrent MI

Analyzing the benefit of ticagrelor tells only part of the story. Evaluating the adverse effects and bleeding caused by ticagrelor was beyond the scope of the present report, 4 but knowledge of adverse effects is important to translate results into clinical practice. In the original trial, 3 dyspnea led to study drug withdrawal 5 to 9 times more often with ticagrelor than with placebo. Life‐threatening bleeding occurred 2 to 3 times more often with ticagrelor than with aspirin alone. The number needed to harm each year with the 90‐mg dose to cause a TIMI major bleed was 169 (95% CI, 106–296), and the number needed to harm with the 60‐mg dose was 216 (95% CI, 129–417). When the number needed to harm is less than the number needed to treat, harm may be more likely than benefit.

---

### Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? [^116iZPTq]. Clinical Cardiology (2012). Low credibility.

Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Because ticagrelor is the first oral, reversible, twice-daily agent, sufficient information on drug interactions is not available. Our objective was to ascertain the safety of ticagrelor with other common medications. The US Food and Drug Administration Complete Response Review indicates that renal adverse events (AEs) and renal function AEs were higher in ticagrelor-treated patients who were concomitantly treated with angiotensin receptor blockers (ARBs) > 50% of study days compared to ticagrelor-treated patients who did not receive ARBs > 50% of study days. Clopidogrel-treated patients showed a trend for an increase in adverse renal events with ARB use. However, this was not as pronounced as that observed with ticagrelor. Dyspnea was also significantly increased in patients on concomitant ticagrelor-ARB compared to ticagrelor without concomitant ARB and clopidogrel (21.4% vs 14.6% vs 9.9%, respectively) as well as angioedema (0.15% vs 0.09%). Furthermore, in patients with a baseline estimated glomerular filtration rate (eGFR) < 30 mL/min, the risk of major bleeding, death, and renal failure was increased in patients on ticagrelor compared to patients on clopidogrel. In patients on ticagrelor, ARBs significantly increased the frequency of renal related AEs, renal function AEs, and dyspnea. Moreover, in patients with a baseline eGFR < 30 mL/min, the risk of major bleeding, death, and renal failure was increased in patients on ticagrelor compared to patients on clopidogrel.

---

### Ticagrelor (Brilinta) [^113hRHsR]. FDA (2024). Medium credibility.

Common adverse reactions (1–10%) associated with the use of ticagrelor PO (also known as Brilinta) include: AF, back pain, bleeding, bradycardia, chest pain, cough, diarrhea, dizziness, fatigue, headache, hypertension, hypotension, nausea and syncope.

---

### Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the GLOBAL LEADERS trial [^116BSFeV]. Journal of the American Heart Association (2021). Medium credibility.

Limitations of the GLOBAL LEADERS trial also apply to this prespecified subgroup analysis and need to be considered. First, GLOBAL LEADERS was an open‐label trial, and therefore participants and investigators were not masked to the components of the treatment strategy. Efforts that were made to minimize bias included a focus on major, objective primary outcomes, namely all‐cause mortality, and adjudicated new Q‐wave MI. Investigator reporting for bleeding, MI, stroke, and stent thrombosis was used without central adjudication to ascertain secondary outcomes. Bias and random misclassification can therefore not be excluded for these secondary outcomes. However, GLOBAL LEADERS was monitored for event under‐reporting and consistency of event definitions. Second, the ACS and SCAD subgroups varied in important baseline characteristics that may suggest a lower risk of bleeding in adults with ACS. Specifically, adults with ACS were younger and less likely to have hypertension, hypercholesterolemia, and to be active smokers compared with adults with SCAD. Furthermore, PCI in adults with ACS was more often performed using radial access compared with adults with SCAD. These baselines differences would suggest that the incidence of bleeding should be lower in adults with ACS versus SCAD throughout the duration of follow‐up. However, our study only identified a treatment‐by‐subgroup interaction for BARC‐grade 3 or 5 bleeding from 30 days to 1 year. Therefore, the withdrawal of aspirin and the continuation of treatment with continuation of ticagrelor monotherapy in adults with ACS likely accounts for the treat‐by‐subgroup interaction for BARC‐grade 3 or 5 bleeding in our study. Third, non‐adherence was more common in the experimental strategy than in the control group for both the ACS and SCAD subgroups. This was driven primarily by dyspnea in participants receiving ticagrelor and was largely limited to the first year of treatment. Furthermore, the rate of non‐adherence of the experimental regimen in our trial compared favorably with those reported in other large outcome trials involving ticagrelor for various indications. Fourth, PCI in the GLOBAL LEADERS trial was standardized by uniform implantation of biodegradable polymer‐based biolimus A9‐eluting stents and bivalirudin administration whenever indicated or feasible. Although the choice of anticoagulant and stent in GLOBAL LEADERS may not represent prevalent clinical practice, these treatments were used comparably in the experimental and reference strategy groups and unlikely to bias the results of our study. In addition, guidelines updated since the initiation of the GLOBAL LEADERS trial now recommend 6 months of DAPT after PCI in adults with SCAD versus the 1 year of DAPT that was used in our trial. A shorter duration of DAPT would likely reduce the incidence of bleeding in the reference strategy group and provide further support for avoiding monotherapy with a P2Y12 inhibitor in adults with SCAD. Finally, GLOBAL LEADERS was negative in the main analysis of the primary outcome in the overall population, neither the ACS nor SCAD analysis were powered to detect between‐group differences in clinical outcomes or treatment‐by‐subgroup interactions and there was no formal procedure planned to account for multiple testing. Our results should therefore be considered exploratory in nature. Strength of this subgroup analysis include its prespecified nature, the stratification of randomization by type of presentation, and the large sample size of GLOBAL LEADERS, which means that the analyzed ACS and SCAD populations are larger than the populations included in most randomized trials in patients with coronary artery disease.

---

### Ticagrelor [^1134uPtU]. FDA (2025). Medium credibility.

Patients were treated for at least 12 months and up to 48 months with a median follow up time of 33 months.

Patients were predominantly male (76%) Caucasian (87%) with a mean age of 65 years, and 99.8% of patients received prior aspirin therapy.

The Kaplan-Meier curve (Figure 13) shows time to first occurrence of the primary composite endpoint of CV death, non-fatal MI or non-fatal stroke.

Figure 13: Time to First Occurrence of CV death, MI or Stroke (PEGASUS)

Ti = Ticagrelor BID; CI = Confidence interval; HR = Hazard ratio; KM = Kaplan-Meier; N = Number of patients.

Both the 60 mg and 90 mg regimens of ticagrelor in combination with aspirin were superior to aspirin alone in reducing the incidence of CV death, MI or stroke. The absolute risk reductions for ticagrelor plus aspirin vs. aspirin alone were 1.27% and 1.19% for the 60 and 90 mg regimens, respectively. Although the efficacy profiles of the two regimens were similar, the lower dose had lower risks of bleeding and dyspnea.

Table 8 shows the results for the 60 mg plus aspirin regimen vs. aspirin alone.

Table 8: Incidences of the primary composite endpoint, primary composite endpoint components, and secondary endpoints (PEGASUS)

In PEGASUS, the relative risk reduction (RRR) for the composite endpoint from 1 to 360 days (17% RRR) and from 361 days and onwards (16% RRR) were similar.

The treatment effect of ticagrelor 60 mg over aspirin appeared similar across most pre-defined subgroups, see Figure 14.

Figure 14: Subgroup analyses of ticagrelor 60 mg (PEGASUS)

Note: The figure above presents effects in various subgroups all of which are baseline characteristics and most of which were pre-specified. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

---

### Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial [^112QRVTF]. Journal of the American Heart Association (2015). Low credibility.

Sources of Funding

The PLATO study was funded by AstraZeneca. Support for the analysis and interpretation of results and preparation of the manuscript was provided through funds to the Uppsala Clinical Research Center and Duke Clinical Research Institute as part of the Clinical Study Agreement.

---

### The role of ticagrelor in acute ischaemic stroke and high-risk TIA management [^111s4CTU]. Journal of Neurology (2021). Medium credibility.

Following subgroup analysis, CYP2C19 carriers (associated with a reduced effect of clopidogrel), had a significant reduction in 90-day high platelet reactivity from 35.4% in the clopidogrel group to 10.8% in the ticagrelor group (p < 0.001). There was no significant difference in major bleeding between the two groups. Of note, more patients discontinued treatment in the ticagrelor arm, because of side effects including epistaxis and dyspnoea.

Comments: This study demonstrated a non-significant trend towards a reduction in risk of further stroke at 90 days in patients taking ticagrelor with aspirin rather than ticagrelor with clopidogrel. The lower rate of high platelet reactivity is of interest, but in the absence of a clinically meaningful difference in a relevant outcome measure it remains unclear whether ticagrelor should be used as an alternative to clopidogrel in clinical practice.

Some caution is also required in the interpretation of results regarding the 24 pre-specified secondary outcome measures since there is a lack of effective correction for multiple comparisons. In addition, the differences in clopidogrel metabolism in different ethnic groups means that results may not be applicable to cohorts of non-Chinese ethnicities.

Wang et al. (2019). BMJ. 365:l2211(1–11).

---

### The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient outcomes (PLATO) trial [^112ZuSHu]. European Heart Journal (2014). Low credibility.

Statistical analysis

Patient characteristics were compared according to sex using χ² and Wilcoxon rank-sum tests. Cox proportional-hazards models were used to analyse the association between sex subgroup and the primary composite endpoint and each of the secondary endpoints and major bleeding endpoints.

Adjustment variables besides geographic region also included age, weight, height, body mass index, waist circumference, heart rate, systolic blood pressure, smoking status, white blood cell count, haemoglobin level, creatinine clearance, troponin level, time from onset of symptoms to randomization, changes in electrocardiogram (ECG) at entry (ST-elevation or ST-depression), Killip class at entry, glycoprotein inhibitors (GPIs) at entry, prior MI, prior stroke, prior transient ischaemic attack (TIA), prior PCI, prior coronary artery bypass grafting (CABG), prior gastrointestinal bleeding episodes, diabetes, peripheral arterial disease (PAD), dyslipidaemia, angina pectoris, congestive heart failure, final diagnosis, randomized treatment, and treatment approach.

The interaction of sex subgroup with treatment effects was investigated by use of Cox proportional-hazards models. For efficacy endpoints, all analyses were based on the intent-to-treat approach. Bleeding endpoints were analysed up to 7 days after permanent discontinuation, and only in patients who had received at least one dose of the study drug. Dyspnoea rates by gender and randomized treatment at 1 year were estimated using the Kaplan–Meier (KM) method. Hazard ratios (HR) comparing the randomized treatments and the treatment by gender interaction test were derived using a Cox regression model.

The proportional hazard assumption was assessed using the method proposed by Lin et al.based on the cumulative sum of martingale residuals. For the endpoints where the proportional hazard assumption was not met, a piecewise proportional hazard model was used. The cutpoints for the piecewise segments were selected using likelihood ratio tests.

Ventricular pauses by gender and treatment at first week and 30 days were summarized as percentages. Odds ratios comparing randomized treatments and the treatment by gender interaction were derived using a logistic regression model.

All the analyses were performed using SAS ®, version 9.2 (SAS Institute, Gary, NC, USA). Comparisons for exploratory analyses used a two-sided significance level of 0.05 without correction for multiple comparisons.

---

### Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans [^112VFAbF]. Journal of the American College of Cardiology (2013). Low credibility.

Objectives

This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects.

Background

Ticagrelor is a P2Y(12) receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model.

Methods

In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline.

Results

Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline.

Conclusions

Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602).

---

### Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease [^117D9zHp]. Circulation (2018). Low credibility.

Contrary to some previous published studies, we found no evidence of any effect of the ticagrelor regimens on cellular adenosine uptake or plasma adenosine concentration. The reasons for this are unclear since our data show clearly that the assay assessed adenosine uptake over 1 minute in whole blood samples, with the expected baseline levels of adenosine after in vitro addition of 1 µmol/L (indicating efficacy of the stop solution in preventing further adenosine uptake) and almost complete adenosine uptake at 1 minute (indicating efficacy of the stop solution in preventing adenosine generation). Our stop solution for adenosine metabolism included additional inhibitors to those used by Bonello et al, including p-nitrobenzylthioinosine as an additional inhibitor of adenosine uptake and iodotubercidin as a potent adenosine kinase inhibitor, and therefore may have been more effective. In agreement with our findings, a recent study in healthy volunteers found no impact of ticagrelor on plasma adenosine level. Furthermore, using the same methodology, we found no impact of ticagrelor on plasma adenosine concentration in acute coronary syndrome patients awaiting coronary artery bypass graft surgery, suggesting that the nature of the patient population in our current study was not a determinant of the findings. In vitro studies predict little effect of ticagrelor on adenosine uptake at therapeutic concentrations due to high levels of plasma protein binding that limit the free ticagrelor available to bind to ENT-1. On the other hand, an effect of ticagrelor on adenosine uptake is more clearly seen at approximately therapeutic concentrations in the absence of plasma proteins. Since ticagrelor has been shown to induce a leftward shift in the dose-response curves for intravenous adenosine in studies of coronary blood flow responses and dyspnea severity, it remains likely that ticagrelor has an impact on the kinetics of adenosine uptake in vivo at the tissue level, such as in myocardium, that is not detected by the currently available blood assays, and more work is required to assess this.

---

### Secondhand nicotine vaping at home and respiratory symptoms in young adults [^1151i7Qt]. Thorax (2022). Medium credibility.

RESULTS

Study population

Among the 2090 study participants, about half were Hispanic white (51.8%) and male (50.4%; table 1). The distribution of the demographic factors of participants with respiratory symptoms was largely similar to that of the overall population, except that participants with shortness of breath were more likely to be female (shortness of breath participants: 70.2% female versus non-shortness of breath participants: 43.4% female, p < 0.01).

Prevalence of vaping and smoking exposure

The prevalence of secondhand nicotine vape exposure increased from 11.7% to 15.6% from wave 1 to wave 4 in the study population (figure 1), while the prevalence of secondhand smoking decreased from 26.6% to 20.6%. Past 30-day use of cigarettes, e-cigarettes and cannabis (wave 3 to wave 4) increased over the study period. None of those changes were statistically significant except for the observed increase of primary vaping or smoking from 12.1% in wave 1 to 34.0% in wave 4 (p < 0.001).

A majority of the participants (76.0%–93.1%) who had secondhand nicotine vape exposure during any of the study waves was also likely to have personal use of tobacco or cannabis products or secondhand exposure to combustible products (online supplemental table S2). For example, during wave 4, out of the participants who reported secondhand nicotine vape (n = 223), only 6.9% had no other vaping or smoking related exposures, while 11.5% had primary vaping or smoking, but no secondhand smoking exposure, 33.2% had secondhand smoking, but no primary vaping or smoking exposure, and 48.4% had both secondhand smoking and primary vaping or smoking exposure.

Prevalence of respiratory symptoms

Over the study period, an increase in the prevalence of wheeze and bronchitic symptoms was observed in the study population (not statistically significant). The prevalence increased from 12.3% to 14.9% for wheeze and 19.4% to 26.0% for bronchitic symptoms (figure 2). The prevalence of shortness of breath did not show any clear trend over time, with prevalence of 16.5% in wave 2, 18.1% in wave 3 and 17% in wave 4.

---

### Secondhand nicotine vaping at home and respiratory symptoms in young adults [^113owCNR]. Thorax (2022). Medium credibility.

Rationale

Despite high prevalence of e-cigarette use (vaping), little is currently known regarding the health effects of secondhand nicotine vape exposure.

Objective

To investigate whether exposure to secondhand nicotine vape exposure is associated with adverse respiratory health symptoms among young adults.

Method

We investigated the effect of secondhand nicotine vape exposure on annually reported wheeze, bronchitic symptoms and shortness of breath in the prospective Southern California Children Health Study cohort. Data were collected from study participants (n = 2097) with repeated annual surveys from 2014 (average age: 17.3 years) to 2019 (average age: 21.9). We used mixed effect logistic regression to evaluate the association between secondhand nicotine vape and respiratory symptoms after controlling for relevant confounders.

Results

Prevalence of secondhand nicotine vape increased from 11.7% to 15.6% during the study period in this population. Prevalence of wheeze, bronchitic symptoms and shortness of breath ranged from 12.3% to 14.9%, 19.4% to 26.0% and 16.5% to 18.1%, respectively, during the study period. Associations of secondhand nicotine vape exposure with bronchitic symptoms (OR 1.40, 95% CI 1.06 to 1.84) and shortness of breath (OR 1.53, 95%CI 1.06 to 2.21) were observed after controlling for vaping, active and passive exposure to tobacco or cannabis, and demographic characteristics (age, gender, race/ethnicity and parental education). Stronger associations were observed when analysis was restricted to participants who were neither smokers nor vapers. There were no associations with wheezing after adjustment for confounders.

Conclusion

Secondhand nicotine vape exposure was associated with increased risk of bronchitic symptoms and shortness of breath among young adults.

---

### Ticagrelor (Brilinta) [^111avzij]. FDA (2025). Medium credibility.

6 ADVERSE REACTIONS

The following adverse reactions are also discussed elsewhere in the labeling:

Bleeding [see Warnings and Precautions (5.1)]
Dyspnea [see Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

BRILINTA has been evaluated for safety in more than 58,000 patients.

Bleeding in PLATO (Reduction in risk of thrombotic events in ACS)

Figure 1 is a plot of time to the first non-CABG major bleeding event.

Figure 1 - Kaplan-Meier estimate of time to first non-CABG PLATO-defined major bleeding event (PLATO)

Frequency of bleeding in PLATO is summarized in Tables 1 and 2. About half of the non-CABG major bleeding events were in the first 30 days.

No baseline demographic factor altered the relative risk of bleeding with BRILINTA compared to clopidogrel.

In PLATO, 1584 patients underwent CABG surgery. The percentages of those patients who bled are shown in Figure 2 and Table 2.

Figure 2 - 'Major fatal/life-threatening' CABG-related bleeding by days from last dose of study drug to CABG procedure (PLATO)

X-axis is days from last dose of study drug prior to CABG.

The PLATO protocol recommended a procedure for withholding study drug prior to CABG or other major surgery without unblinding. If surgery was elective or non-urgent, study drug was interrupted temporarily, as follows: If local practice was to allow antiplatelet effects to dissipate before surgery, capsules (blinded clopidogrel) were withheld 5 days before surgery and tablets (blinded ticagrelor) were withheld for a minimum of 24 hours and a maximum of 72 hours before surgery. If local practice was to perform surgery without waiting for dissipation of antiplatelet effects capsules and tablets were withheld 24 hours prior to surgery and use of aprotinin or other hemostatic agents was allowed. If local practice was to use IPA monitoring to determine when surgery could be performed both the capsules and tablets were withheld at the same time and the usual monitoring procedures followed.

---

### Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: a network meta-analysis [^112Dfzzc]. Clinical Cardiology (2021). Medium credibility.

Although ticagrelor has pharmacokinetic advantages over prasugrel, two indirect comparison meta‐analyses showed prasugrel might be more effective than ticagrelor for preventing ST. 12, 13 However, subsequent head to head comparison studies, including the PRAGUE‐18 study (9/587 vs. 7/627), ISAR‐REACT 5 trial (22/1990 vs. 12/1994) and TOTAL trial (31/2188 vs. 30/1244), showed that patients treated with ticagrelor had a similar rate of ST compared to those treated with prasugrel. 14, 15, 16 Consistently, our network meta‐analysis confirmed the similar efficacy for the prevention of ST between prasugrel and ticagrelor (OR = 0.86, 95% CI = 0.22–2.3).

More interestingly, several recent real‐world studies actually found that ticagrelor was not superior to clopidogrel for preventing ST, 38, 39, 40 which was different from PLATO trial as well as our study. This might be explained by the following reasons. A potent mediator for efficacy attenuation of ticagrelor outside RCT might be decreased compliance because of the higher rate of adverse events (dyspnea, bleeding), administration of the drug twice daily and higher costs. 38, 39, 40 Additionally, the overall improvement in the clinical outcomes of patients with ACS 41 might be another possible explanation for the diminished benefit of ticagrelor in the modern era; particularly, this might be driven by progress in the use of drug‐eluting stents 42 and poststenting care.

Finally, it should be noted that some patients still experience ST events in spite of DAPT. This might partly result from the inadequate anti‐platelet activity of DAPT. Besides, procedural "trauma" to the vessel and inadequate stent deployment play a role in the development of ST. 5 Therefore, further research is needed to identify the mechanism of ST among individuals underwent PCI.

---

### Ticagrelor (Brilinta) [^1153qWKk]. FDA (2024). Medium credibility.

Regarding the use of ticagrelor PO (also known as Brilinta) in patients with chronic liver disease, Child-Pugh B (moderate):

- Use with caution.
- Monitor for toxicity.
- - Carefully weigh the risks versus the benefits of treatment, considering the probable increase in exposure to ticagrelor.

---

### Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction [^116TVunr]. Clinical Cardiology (2021). Medium credibility.

3 DISCUSSION

STEMI is a common clinical cardiovascular emergency. In recent years, the incidence of STEMI has been increasing year by year. Platelet activation and aggregation is the initial link in the onset of STEMI, which has important significance in the onset of STEMI. Therefore, antiplatelet therapy is of great significance in STEMI treatment. Ticagrelor is the first reversibly binding, oral, direct‐acting P2Y₁₂ receptor antagonist that binds reversibly and noncompetitively to the P2Y₁₂ receptor. Recently, studies showed that standard‐dose ticagrelor has a more rapid onset of effect and a greater inhibition of platelet aggregation compared with high‐dose clopidogrel therapy. 10, 11 At present, the application of ticagrelor in STEMI treatment has been unanimously recommended by many guidelines. However, standard‐dose ticagrelor is associated with a significant increase in the risk of bleeding, incidence of dyspnea 12, 13, 14 and higher discontinuation rates due to adverse effects compared with clopidogrel. Studies have reported that a switch to a high‐dose of clopidogrel, ticagrelor, or prasugrel may be indicated. 15 Previous studies demonstrated that a half‐dose of ticagrelor had an inhibitory effect on platelet aggregation that was better than clopidogrel 16, 17, 18 and even that half‐dose ticagrelor produced a similar effect of platelet reactivity inhibition as standard‐dose ticagrelor in Chinese patients. 19

---

### Ticagrelor (Brilinta) [^1147cut5]. FDA (2024). Medium credibility.

The dosage of ticagrelor PO for prevention of transient ischemic attack in adults is:

- **Loading**: 180 mg PO once
- **Maintenance**: 90 mg PO BID a duration of up to 30 days

---

### "Real-world" comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States [^115SVgDh]. Catheterization and Cardiovascular Interventions (2016). Low credibility.

As with all observational research, there are inherent limitations in the conclusions to be drawn from the data, and the current study can only demonstrate associations, not causality. In this database, event rates may be underestimated because events that occurred at a non‐IMS Health CDM hospital site were not available for analysis. While the study included available baseline disease information back to 2008, events prior to this date were not captured. Stent thrombosis events may be underestimated, as a specific ICD‐9‐CM code for stent thrombosis does not exist. The relevance of including CHF as a component endpoint may be questioned. However, as the difference in periprocedural MI between the more potent ADP receptor inhibitors and clopidogrel was more apparent in TRITON‐TIMI 38 6 than in PLATO 7, in a payer database, the presence of CHF may be an indicator of the severity and extent of the presenting infarction. However, the diagnosis of CHF may also have been a marker of the difference in rates of dyspnea as a side effect of ticagrelor 7. Additionally, all medical conditions, either at baseline or used to determine outcomes, were derived from a healthcare administrative database that includes orders from hospital CDM systems with no access to medical charts. Medication switching and adherence to prescribed therapy through the study follow‐up period were not assessed, given only hospital CDM records were used without access to outpatient pharmacy data. Likewise, over‐the‐counter medications, especially aspirin (use or dose), were not available in the database. Despite the use of a propensity‐matched cohort, several potential confounders were not available for analysis, including patient socioeconomic status, body mass index, and weight. Similarly, provider experience (e.g. years in practice, case volume, and case selection) or access to drug, (e.g. formulary inclusion) which may influence the choice of medications were not available from this data source. Geographic imbalances existed, with 64% of the study population located in the Southern US. Finally, the ACS‐PCI study selection criteria more closely represented the population indicated for prasugrel in the US, as ticagrelor is also indicated for patients with ACS not managed by PCI. Therefore, these results may not be generalizable to other populations.

---

### Ticagrelor (Brilinta) [^1114n9Gt]. FDA (2024). Medium credibility.

Labeled indications for Ticagrelor (also known as Brilinta) include:

- Treatment of cardiovascular mortality in adults with myocardial infarction
- Prevention of transient ischemic attack in adults
- Prevention of cardiovascular mortality in adults with acute coronary syndromes
- Prevention of stroke in adults with acute ischemic stroke (NIH Stroke Scale score ≤ 5)

---

### Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study [^114qxj2a]. British Journal of Haematology (2019). Medium credibility.

Safety

The proportion of patients experiencing AEs during treatment was similar across the groups, with no relation to ticagrelor dose (Table 2). One patient (placebo) experienced a serious AE of hepatic ischaemia and discontinued treatment. One patient (ticagrelor 45 mg) experienced an AE of exertional dyspnoea of severe intensity on day 86 at the end of the 12‐week treatment period, leading to treatment discontinuation. Neither of these events were judged by the investigator to be study drug‐related. No deaths occurred during the study.

Table 2
Summary of adverse events in safety population (patients taking study drug)

Most AEs were mild or moderate, with the most common AEs being headache, arthralgia and pain in extremities. Severe AEs were experienced by 7 (26.9%), 4 (13.3%) and 3 patients (10.0%) in the ticagrelor 10 mg, ticagrelor 45 mg and placebo groups, respectively. The proportion of patients experiencing a serious AE during treatment was similar across the groups (Table 2). No serious AEs were considered to be treatment‐related as judged by the investigator. The most common serious AE was sickle cell anaemia with crisis.

Overall, six patients (2/group) experienced a total of six bleeding events, none of which were major. Five events were classified as clinically relevant, non‐major bleeding events: nose bleed (2 patients on ticagrelor 45 mg and 1 on placebo); blood in urine (one patient on ticagrelor 10 mg); and vaginal bleeding (one placebo patient). One event of haematuria was classified as minor bleeding (one patient on ticagrelor 10 mg). Two bleeding events were considered by the investigator to be treatment‐related: one case of intermittent vaginal bleeding (placebo) and one of bilateral epistaxis (ticagrelor 45 mg).

There were no clinically meaningful differences across the groups in changes from baseline in haematology, clinical laboratory results or vital signs.

---

### Review of the ticagrelor trials evidence base [^1132B2Xz]. Journal of the American Heart Association (2024). Medium credibility.

CORONARY ARTERY DISEASE

DAPT with clopidogrel is recommended for PCI in patients with chronic CAD. ALPHEUS randomized patients undergoing high‐risk elective PCI to DAPT with either ticagrelor or clopidogrel (Table 4). There were no differences in the rates of periprocedural MI or myocardial injury (troponin elevated greater than 5 times the upper limit of normal without clinical ischemia) within 48 hours or in BARC type 3 or 5 major bleeding, nor were there differences in ischemic end points at 30 days, but there were higher rates of nuisance or minor bleeding, dyspnea, and treatment discontinuation with ticagrelor.

CABG produces an intense inflammatory reaction and activated platelet function. Aspirin improves saphenous vein graft patency and reduces ischemic events. Studies of DAPT with clopidogrel after CABG have produced conflicting results. There have been 3 recent trials evaluating ticagrelor for this indication, also with conflicting results. The DACAB trial randomized patients to DAPT with ticagrelor, ticagrelor monotherapy, or aspirin monotherapy. Compared with aspirin monotherapy, DAPT significantly improved vein graft patency at 1 year, due to the unexpectedly high 23.5% occlusion rate in the aspirin monotherapy group, whereas ticagrelor monotherapy did not. The TiCAB study randomized patients to ticagrelor monotherapy or aspirin monotherapy. There was no difference in the composite outcome of cardiovascular death, MI, repeat revascularization, and stroke at 1 year in an interim analysis, or in the individual ischemic end points, so the trial was stopped for futility. The POPular‐CABG trial randomized patients to DAPT with ticagrelor versus aspirin monotherapy with no difference in vein graft occlusion at 1 year. One meta‐analysis including observational trials and older randomized trials found that DAPT with ticagrelor or clopidogrel improved vein graft patency rates compared with aspirin monotherapy, but increased major bleeding. Another meta‐analysis of 4 ticagrelor randomized clinical trials also showed that DAPT with ticagrelor compared with aspirin monotherapy decreased vein graft failure rates, but increased clinically important bleeding events with no difference in major cardiovascular and cerebrovascular events. Additionally, there were no differences between ticagelor monotherapy and aspirin monotherapy.

---

### Ticagrelor (Brilinta) [^112WTc93]. FDA (2024). Medium credibility.

The dosage of ticagrelor PO for prevention of cardiovascular mortality in adults with acute coronary syndromes is:

- **Loading**: 180 mg PO once
- **Maintenance**: 90 mg PO BID for 1 year followed by 60 mg twice daily thereafter

---

### The TICONC (ticagrelor-oncology) study: implications of P2YInhibition for metastasis and cancer-associated thrombosis [^1163zTmh]. JACC: CardioOncology (2020). Medium credibility.

Ticagrelor has not been previously tested in vivo for its antiplatelet effects in a cancer population. In this crossover trial (TICONC), we compared the efficacy of ticagrelor and aspirin monotherapy with DAPT on the activation of unstimulated platelets isolated from patients with advanced metastatic breast or colorectal cancer. Supporting the results of the in vitro study, in the absence of exogenously added ADP, ticagrelor significantly reduced the aggregatory response of platelets isolated from patients with higher levels of spontaneous platelet aggregation.

The mechanisms behind platelet hyperreactivity, the elevated activity level of circulating platelets, is still poorly understood, but increased spontaneous aggregation has historically been shown to correlate with poor prognosis in patients with myocardial infarction. Platelet hyperreactivity in a cancer population has been previously reported; however, the possible effects of antiplatelet agents on this population were not considered in this previous study of a small patient cohort of a mixed cancer population. We considered only 2 major cancers to understand any differential response to treatment between groups. In contrast to patients with colorectal cancer, platelets from normal healthy donors and patients with breast cancer had similar lower levels of spontaneous aggregation. Although in vitro monotherapy treatment with aspirin was ineffective at blocking cellular aggregation, it significantly increased the level of platelet aggregation of platelets from donors whose level of spontaneous platelet aggregation was initially low. Further study is necessary to elucidate the mechanisms behind these effects.

Ticagrelor has been widely adopted in populations of patients with high-risk coronary syndromes due to its increased efficacy and reduced mortality rates compared with other P2Y 12 antagonists (e.g. clopidogrel), with the most common side effects being dyspnea and minor bleeding. However, the use of this antiplatelet agent has not previously been tested in a cancer population. In the present study, 1 colorectal cancer patient presented with hematuria during the combined aspirin and ticagrelor period, which resolved once DAPT was stopped.

---

### Ticagrelor (Brilinta) [^117WMwp8]. FDA (2024). Medium credibility.

Regarding the use of ticagrelor PO (also known as Brilinta) in patients with chronic liver disease, Child-Pugh A (mild):

- Use acceptable.
- No dose adjustment required.
- Monitor for toxicity.

---

### Ticagrelor (Brilinta) [^113EdENh]. FDA (2024). Medium credibility.

Regarding the use of ticagrelor PO (also known as Brilinta) in patients with chronic liver disease, Child-Pugh C (severe):

- Do not use.

---

### Ticagrelor (Brilinta) [^111ufnNy]. FDA (2025). Medium credibility.

Patients were treated for at least 12 months and up to 48 months with a median follow up time of 33 months.

Patients were predominantly male (76%) Caucasian (87%) with a mean age of 65 years, and 99.8% of patients received prior aspirin therapy.

The Kaplan-Meier curve (Figure 13) shows time to first occurrence of the primary composite endpoint of CV death, non-fatal MI or non-fatal stroke.

Figure 13 – Time to First Occurrence of CV death, MI or Stroke (PEGASUS)

Ti = Ticagrelor BID, CI = Confidence interval; HR = Hazard ratio; KM = Kaplan-Meier; N = Number of patients.

Both the 60 mg and 90 mg regimens of BRILINTA in combination with aspirin were superior to aspirin alone in reducing the incidence of CV death, MI or stroke. The absolute risk reductions for BRILINTA plus aspirin vs. aspirin alone were 1.27% and 1.19% for the 60 and 90 mg regimens, respectively. Although the efficacy profiles of the two regimens were similar, the lower dose had lower risks of bleeding and dyspnea.

Table 8 shows the results for the 60 mg plus aspirin regimen vs. aspirin alone.

In PEGASUS, the relative risk reduction (RRR) for the composite endpoint from 1 to 360 days (17% RRR) and from 361 days and onwards (16% RRR) were similar.

The treatment effect of BRILINTA 60 mg over aspirin appeared similar across most pre-defined subgroups, see Figure 14.

Figure 14 – Subgroup analyses of ticagrelor 60 mg (PEGASUS)

Note: The figure above presents effects in various subgroups all of which are baseline characteristics and most of which were pre-specified. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.

---

### Ticagrelor (Brilinta) [^116Vi6Hk]. FDA (2024). Medium credibility.

Regarding the use of ticagrelor PO (also known as Brilinta) in patients with eGFR 0–90 mL/min/1.73 m²:

- Use acceptable.
- No dose adjustment required.

---

### New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^111fXfM6]. Chest (2012). Medium credibility.

Ticagrelor — mechanism and pharmacodynamics: Ticagrelor is "an orally active agent belonging to the cyclopentyl-triazolopyrimidine class; ticagrelor acts as a direct inhibitor of P2Y12", binding at a site distinct from ADP and blocking receptor activation "in a noncompetitive fashion, likely through an allosteric mechanism". It "does not require hepatic conversion to an active metabolite", achieves inhibition "within 30 min", and the peak inhibitory effect is "about 2 h after a loading dose of ticagrelor of 180 mg or a maintenance dose of 90 mg bid".

---

### Ticagrelor monotherapy versus ticagrelor with aspirin in acute coronary syndrome patients with a high risk of ischemic events [^116Mgsh4]. Circulation: Cardiovascular Interventions (2021). Medium credibility.

[Figure: see text].

---

### Ticagrelor (Brilinta) [^114Unmk1]. FDA (2024). Medium credibility.

The dosage of ticagrelor PO for prevention of stroke in adults with acute ischemic stroke (NIH Stroke Scale score ≤ 5) is:

- **Loading**: 180 mg PO once
- **Maintenance**: 90 mg PO BID a duration of up to 30 days

---

### New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^111MpKBq]. Chest (2012). Medium credibility.

Elinogrel in INNOVATE-PCI and planned phase 3 — In the INNOVATE-PCI study, 652 patients scheduled for nonurgent PCI were randomized to clopidogrel (300 to 600 mg load followed by 75 mg daily thereafter) or to elinogrel (80 mg IV bolus followed by oral dosing of 50, 100, or 150 mg bid thereafter), and the Data Safety Monitoring Board recommended discontinuation of the 50-mg oral dose and suggested increasing the IV dose to 120 mg, with greater platelet inhibition observed with elinogrel than clopidogrel; dyspnea occurred more frequently and abnormal liver function tests were more common with elinogrel but appeared to resolve over time; a phase 3 program is planned in aspirin-treated patients with prior MI, randomizing to elinogrel or placebo for approximately 29 months with a composite primary efficacy outcome of cardiovascular mortality, MI, or stroke, and a phase 3 trial in ACS evaluating IV and oral elinogrel is likely to follow.

---

### Ticagrelor (Brilinta) [^114Us21t]. FDA (2024). Medium credibility.

Uncommon adverse reactions (less than 1%) associated with the use of ticagrelor PO (also known as Brilinta) include: gynecomastia, intracranial hemorrhage and ↑ serum uric acid.

---

### A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy [^116vcu4u]. Chest (2014). Low credibility.

We report a case of significant pulmonary hemorrhage developing shortly after commencing ticagrelor and aspirin therapy and requiring coronary artery bypass grafting to safely cease the antiplatelet therapy. Lung biopsy findings were consistent with drug-induced lung injury. Clinicians should be aware of this significant adverse event with this drug class.

---

### New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [^113ojNCx]. Chest (2012). Medium credibility.

ADP receptor antagonists (reversible P2Y12 inhibitors) — Three reversible P2Y12 inhibitors are in phase 3 development: cangrelor, ticagrelor, and elinogrel. In contrast to the thienopyridines, these agents do not require metabolic activation and they bind directly and reversibly to the P2Y12 receptor, and because of reversible binding their inhibitory effects decrease as drug concentrations fall.

---

### Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance [^114UhhjM]. Journal of the American College of Cardiology (2014). Low credibility.

This review constitutes a critical evaluation of recent publications that have described an additional mode of action of the P2Y12 receptor antagonist ticagrelor. The effect is mediated by inhibition of the adenosine transporter ENT1 (type 1 equilibrative nucleoside transporter), which provides protection for adenosine from intracellular metabolism, thus increasing its concentration and biological activity, particularly at sites of ischemia and tissue injury where it is formed. Understanding the mode of action of ticagrelor is of particular interest given that its clinical profile, both in terms of efficacy and adverse events, differs from that of thienopyridine P2Y12 antagonists.

---

### Understanding the adverse effects of ticagrelor in practice… [^1162aGGE]. JAMA Network (2016). Excellent credibility.

Patients discontinue treatment for a variety of reasons. These include the perception that the treatment is not working, the expense, adverse effects, and simply forgetting to take the medication. Some adverse effects are intolerable or are so dangerous that the risk of continuing treatment outweighs the potential benefit. The placebo comparator allows one to gain insight into the reasons for discontinuation specific to ticagrelor. Discontinuation rates were much higher in the PEGASUS-TIMI 54 trial than in the PLATO trial, 8 presumably because minor symptoms are better tolerated and may be overlooked in the early phase of an acute coronary syndrome.

Bleeding and dyspnea were each about 5 times more common as a reason for discontinuing treatment with ticagrelor than with placebo, with absolute discontinuation rates about 5% higher for patients who were receiving ticagrelor than for patients who were receiving placebo owing to each of these 2 adverse effects. The majority of the excess in discontinuation rates with regard to treatment with ticagrelor vs placebo was related to these 2 adverse effects. Dyspnea occurred early, with a median time to discontinuation due to dyspnea of about 10 days. Dyspnea was mild or moderate in severity in the majority of cases. This well-described adverse effect of ticagrelor does not manifest as abnormal pulmonary function test results and is quickly reversible after discontinuation.

It does, however, require a thorough conversation because the patient and other health care professionals must be aware that the development of dyspnea ought not lead to anxiety, cessation of therapy without initiation of another P2Y12 inhibitor, or an expensive evaluation of patients who develop such symptoms in the 1 to 2 weeks after initiation of therapy. Bleeding, the other leading cause of discontinuation of ticagrelor, was considered to be "nonmajor" in 86% of cases in which it was the reason for discontinuation. But bleeding was classified as minor with the decrease in hemoglobin level of less than 5 g/dL, a definition that may not be minor from a patient's perspective, especially since it was troublesome enough to lead the patient to stop a potentially lifesaving therapy.

---

### Long-term tolerability of ticagrelor after myocardial infarction… [^1113fyke]. JAMA Network (2016). Excellent credibility.

The majority of patients who discontinued treatment with ticagrelor owing to dyspnea or bleeding did so early after randomization. Of those who discontinued treatment because of dyspnea, the median times were 8 and 11 days in the 90- and 60-mg arms, respectively. Of those that discontinued treatment because of bleeding, the median times were 86 and 156 days in the 90- and 60-mg arms, respectively. When initiated in stable outpatients for secondary prevention, treatment with ticagrelor compared with placebo resulted in more patients discontinuing treatment, primarily owing to adverse events that did not meet the regulatory definition of "serious. " The most frequent adverse events driving discontinuation were symptoms of dyspnea and bleeding; however, these adverse events occurred early in the course of treatment, and the majority of cases of bleeding were nonmajor, whereas the majority of cases of dyspnea were mild or moderate in severity.

Among patients who completed 1 year of treatment, subsequent rates of discontinuation were low. By way of comparison, in the PLATO trial, in which the median duration of exposure to study drug was 277 days, dyspnea occurred more frequently with ticagrelor than with clopidogrel (13. 8% vs
7. 8%; P. Similarly, in phase 2 studies including stable patients with atherosclerosis, dyspnea occurred in 10% of patients who received either 50 or 100 mg of ticagrelor over 28 days of exposure. 4 Reasons for the differences may be that dyspnea is not uncommon in the setting of acute coronary syndromes, whereas it would be unexpected in stable outpatients and hence would be more likely to lead to the discontinuation of treatment. To that end, the absolute excess rate of dyspnea was about 5% to 6% in both the PLATO and PEGASUS-TIMI 54 trials.

The excess discontinuation of ticagrelor due to dyspnea generally occurred early, typically within days of exposure, and was generally in response to dyspnea symptoms that were nonserious and characterized as mild or moderate in severity. Although extensive evaluation of the dyspnea induced by ticagrelor has shown no associated cardiovascular or pulmonary harm, a significant proportion of patients still discontinued treatment in response to their mild or moderate symptoms.

---

### Ticagrelor vs prasugrel for acute coronary syndrome in routine care… [^116oaaef]. JAMA Network (2024). Excellent credibility.

The primary composite end point of all-cause mortality, MI, or stroke occurred in 815 individuals receiving ticagrelor and 663 receiving prasugrel. This cohort study found that prasugrel was associated with lower rates of all-cause mortality, MI, or stroke compared with ticagrelor in individuals with ACS undergoing an invasive treatment strategy in routine care, particularly in individuals with ST-segment elevation MI. The findings suggest that carefully designed database studies can complement and extend findings from randomized clinical trials, informing guidelines and clinical decision-making. At 1-year follow-up, the primary end point occurred in 815 individuals in the ticagrelor group vs 663 in the prasugrel group. Sensitivity analyses confirmed consistent results.

Propensity score matching with extended preexposure characteristics showed an association of ticagrelor with more events related to the primary composite end point. Results for the negative control outcome of influenza revealed no significant difference between the treatment groups. In the setting of routine care, this cohort study found that prasugrel was associated with a significantly lower incidence of the primary composite end point compared with ticagrelor in individuals discharged from the hospital after undergoing an invasive treatment strategy for ACS, particularly those with STEMI. In contrast, no significant difference in major bleeding between prasugrel and ticagrelor was found.

In this cohort study of 17 642 individuals discharged after an invasive treatment strategy for ACS, prasugrel was associated with significantly lower event rates compared with ticagrelor in the primary composite outcome of all-cause mortality, MI, or stroke, without excess bleeding. These findings support the superior effectiveness of prasugrel over ticagrelor observed in IR5. 1 The database study also allowed for robust analyses of ACS subtypes to complement underpowered RCT results.